University of New Mexico

UNM Digital Repository
Nanoscience and Microsystems ETDs

Engineering ETDs

7-12-2014

BIOSENSING OF MATRIX
METALLOPROTEINASE ACTIVITY WITH
CD-FREE QUANTUM DOTS
John Plumley

Follow this and additional works at: https://digitalrepository.unm.edu/nsms_etds
Recommended Citation
Plumley, John. "BIOSENSING OF MATRIX METALLOPROTEINASE ACTIVITY WITH CD-FREE QUANTUM DOTS."
(2014). https://digitalrepository.unm.edu/nsms_etds/9

This Dissertation is brought to you for free and open access by the Engineering ETDs at UNM Digital Repository. It has been accepted for inclusion in
Nanoscience and Microsystems ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact
disc@unm.edu.

John Bryan Plumley
Candidate

Nanoscience and Microsystems
Department

This dissertation is approved, and it is acceptable in quality and form for publication:
Approved by the Dissertation Committee:

Marek Osinski

, Chairperson

Ganesh Balakrishnan

Erin Milligan

Mani Hossein-Zadeh

i

BIOSENSING OF MATRIX METALLOPROTEINASE
ACTIVITY WITH CD-FREE QUANTUM DOTS

by

JOHN BRYAN PLUMLEY
B.S. CHEMICAL ENGINEERING, UNIVERSITY OF NEW
MEXICO, 2008
M.S. NANOSCIENCE AND MICROSYSTEMS, UNIVERSITY
OF NEW MEXICO, 2012

Dissertation
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
Nanoscience and Microsystems
The University of New Mexico
Albuquerque, New Mexico
May, 2014

ii

ACKNOWLEDGEMENTS
I would like to give my heartfelt thanks to my committee chair and advisor Dr. Marek
Osinski, whose guidance and encouragement made this dissertation possible.
I would also like to thank Dr. Ganesh Balakrishnan, Dr. Erin Milligan, and Dr. Mani
Hossein-Zadeh for accepting the position of committee members for my dissertation
defense. Extra special thanks goes to Dr. Erin Milligan for her continued support over the
years and for allowing me the use of her facilities, which were crucial to this research.
Additional gratitude and appreciation goes to all my co-workers at CHTM and high
school interns as well as the CHTM staff for endless support.
Finally, I would like to thank my family and friends for their support during my time in
college.

iii

BIOSENSING OF MATRIX METALLOPROTEINASE ACTIVITY WITH CDFREE QUANTUM DOTS
by
John Bryan Plumley
B.S. Chemical Engineering, University of New Mexico, 2008
M.S. Nanoscience and Microsystems, University of New Mexico, 2012
Ph.D. Nanoscience and Microsystems, University of New Mexico, 2014

ABSTRACT

Quantum dots (QDs) have become attractive in the biomedical field on account of their
superior optical properties and stability, in comparison to traditional fluorophores. QDs
also have properties which make them ideal for complex in vivo conditions. However,
toxicity has been a chief concern in the eventual implementation of QDs for in vivo
applications such as biosensing and tumor imaging. Commercially available QDs contain
a notoriously noxious Cd component and therefore continuous research has gone into
developing QDs without toxic heavy metals, generally Cd, that would still yield
comparable performance in terms of their optical properties. Nonetheless, even in the
case of Cd-free QDs, toxicity should be evaluated on a case by case basis, as other
properties such as size, coating, stability, and charge can affect toxicity of nanomaterials
as well, making it a very complex issue.

With the high promise of QDs in the field of biomedical development as a motivation,
this work strives to develop the efficient and repeatable synthesis of Cd-free QDs with
high stability and luminescence, with proven low toxicity, and the ability to detect active
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matrix metalloproteinase (MMP) in a biosensing system, designed to identify direct
biomarkers for pathological conditions, which in turn would enable early disease
diagnosis and better treatment development.

In this work, highly luminescent ZnSe:Mn/ZnS QDs have been synthesized,
characterized, and modified with peptides with a bioconjugation procedure that utilized
thiol-metal affinity. Experiments aiming at MMP detection were conducted using the
peptide/QD conjugates. In addition, the ApoTox-GloTM Triplex assay was utilized to
evaluate cytotoxicity, and a safe concentration below 0.125 µM was identified for
peptide-coated ZnSe:Mn/ZnS QDs in water. Finally, in contribution to developing an in
vivo fiberoptic system for sensing MMP activity, the QDs were successfully tethered to
silica and MMP detection was demonstrated with the peptide/QD conjugates.

v

Table of Contents

Pages

List of figures ......................................................................................................................x
List of tables......................................................................................................................xx
List of publications......................................................................................................... xxi

1. Introduction to matrix metalloproteinases (MMPs), quantum dots (QDs),
and QD-based biomarker sensing ..............................................................................1
1.1 Matrix metalloproteinases and their potential as biomarkers ..................................1
1.2 Colloidal quantum dots and their merits ..................................................................6
1.3 QD-based MMP biosensing .....................................................................................8
1.4 Objective and scope of dissertation .......................................................................15

2. Synthesis and characterization of ZnSe:Mn/ZnS colloidal quantum dots ...........17
2.1 Synthesis of highly luminescent Cd-free ZnSe:Mn/ZnS quantum dots.................17
2.1.1 Basic chemical reactions ...............................................................................18
2.1.2 Synthesis materials........................................................................................18
2.1.3 Synthesis procedure ......................................................................................19
2.2 Characterization .....................................................................................................22
2.2.1 Transmission electron microscopy ...............................................................23
2.2.2 Energy-dispersive X-ray spectroscopy .........................................................25
2.2.3 X-ray diffraction ...........................................................................................25
2.2.4 Dynamic light scattering ...............................................................................26
2.2.5 Zeta Potential ................................................................................................28
2.2.6 Absorption.....................................................................................................28
2.2.7 Photoluminescence and quantum efficiency.................................................29
vi

2.3 Summary ................................................................................................................32

3. MMP-substrate-peptide conjugation to ZnSe:Mn/ZnS quantum dots .................34
3.1 QD-peptide conjugation .........................................................................................34
3.2 Bioconjugation concept (biosensor assembly).......................................................34
3.3 Bioconjugation process ..........................................................................................35
3.3.1 Materials .......................................................................................................36
3.3.2 Procedure ......................................................................................................36
3.4 Characterization .....................................................................................................37
3.4.1 Dynamic light scattering ...............................................................................37
3.4.2 Zeta Potential ................................................................................................38
3.4.3 Absorption.....................................................................................................39
3.4.4 Photoluminescence and quantum efficiency.................................................40
3.5 Dilution factor determination .................................................................................44
3.6 Photoluminescence of peptide conjugated QDs in cerebrospinal fluid
(CSF) ............................................................................................................................51
3.7 Summary ................................................................................................................52

4. ZnSe:Mn/ZnS QD-based MMP-9 biosensing experiments ......................................53
4.1 ZnSe:Mn/ZnS QDs and peptide-property-dependent effects on QD
fluorescence .................................................................................................................53
4.2 Commercial assay from Anaspec...........................................................................55
4.2.1 Materials .......................................................................................................56
4.2.2 Assay procedure ............................................................................................56
vii

4.2.3 Assay results .................................................................................................56
4.3 Verifying QD emission in the plate reader ............................................................59
4.3.1 Procedure ......................................................................................................60
4.3.2 Results ...........................................................................................................60
4.4 MMP-9 biosensing (positively charged peptide) ...................................................61
4.4.1 Materials .......................................................................................................62
4.4.2 Procedure ......................................................................................................62
4.4.3 Results ...........................................................................................................62
4.5 Characterization of ZnSe:Mn/ZnS QDs with negatively charged peptides ...........64
4.5.1 Optical characterization ................................................................................65
4.6 MMP-9 biosensing (negatively charged peptide) ..................................................67
4.6.1 Materials .......................................................................................................67
4.6.2 Procedure ......................................................................................................67
4.6.3 Results ...........................................................................................................68
4.7 MMP-9 biosensing with varying QD concentration ..............................................69
4.7.1 Materials .......................................................................................................70
4.7.2 Procedure ......................................................................................................70
4.7.3 Results ...........................................................................................................70
4.8 MMP-9 biosensing with varying peptide concentration ........................................72
4.8.1 Materials .......................................................................................................76
4.8.2 Procedure ......................................................................................................76
4.8.3 Results ...........................................................................................................76
4.9 MMP-9 biosensing with dilute peptide concentrations ..................................77

viii

4.9.1 Materials .......................................................................................................81
4.9.2 Procedure ......................................................................................................81
4.9.3 Results ...........................................................................................................82
4.10 Summary ..............................................................................................................83

5. Linking ZnSe:Mn/ZnS quantum dots to silica ..........................................................84
5.1 Silica surface modification ....................................................................................84
5.2 Silica modification processes .................................................................................87
5.2.1 Materials .......................................................................................................88
5.2.2 Procedure 1 ...................................................................................................88
5.3 Optical characterization (Procedure 1) ..................................................................90
5.4 QD pre-modification ..............................................................................................92
5.4.1 Procedure 2 ...................................................................................................93
5.5 Optical characterization (Procedure 2) ..................................................................94
5.5.1 Photoluminescence .......................................................................................95
5.6 Absorption spectra for QD supernatant .................................................................95
5.7 Summary ................................................................................................................97

6. Macrophage cytotoxicity studies with peptide-coated Mn-doped ZnSe/ZnS
quantum dots ...............................................................................................................98
6.1 In vivo QD potential and inherent cytotoxicity ......................................................98
6.2 The ApoTox-GloTM Triplex assay .......................................................................100
6.3 Procedures ............................................................................................................101
6.3.1 Materials .....................................................................................................101

ix

6.3.2 Cell preparation ...........................................................................................101
6.3.3 ZnSe:Mn/ZnS QD synthesis .......................................................................101
6.3.4 QD bioconjugation ......................................................................................102
6.3.5 Cytotoxicity, viability, and luminescence assay .........................................102
6.4 Results ..................................................................................................................103
6.5 Summary ..............................................................................................................117

7. Conclusions and future work ....................................................................................120

List of Figures

Pages

Figure 1.1: Diagram depicting the activation of a MMP-2 enzyme by being
converted from its pro-inactive form to its pro-active form through reactive
oxygen species and its active form from additional proteinase activity ..............................2
Figure 1.2: (a) Size tunable fluorescence emission from multiple colloidal
solutions of CdSe/ZnS QDs and (b) excitation/emission spectra illustrating the
narrow emission and broad absorption ................................................................................7
Figure 1.3: Illustration of a single CdSe/ZnS QD bioconjugate containing an
inorganic CdSe core, an inorganic ZnS shell, an organic polymer coating such as
PEG, and an outer layer of biomolecules such as antibodies, peptides,
streptavidin, DNA, etc .......................................................................................................10
Figure 1.4: Biosensor setup illustrating the approach to utilizing QD-modified
optical fibers to quantify MMP activity by exciting the QDs with light through

x

one input of the fiber coupler and subsequently measuring light emission at the
output by a detector array at the output of a spectrometer .................................................14
Figure 1.5: Illustration of QD fluorescence (a) before and (b) after the surface
peptide is cleaved ...............................................................................................................15

Figure 2.1: (a) The colloidal synthesis of ZnSe:Mn/ZnS QDs was done in a
strictly air-free atmosphere, with precursors prepared under Ar atmosphere and
(b) ZnSe:Mn/ZnS QDs synthesized in octadecene illuminated with a blacklight at
high tempterature (235.7 °C), indicating their thermal stability ........................................20
Figure 2.2: (a)-(f) transmission electron microscopy images of ZnSe:Mn/ZnS
QDs. The scale bars are 20 nm ..........................................................................................24
Figure 2.3: EDS spectrum for ZnSe:Mn/ZnS QDs confirming the presence of Zn,
Se, Mn, and S .....................................................................................................................25
Figure 2.4: Powder XRD spectrum for ZnSe:Mn/ZnS QDs .............................................26
Figure 2.5: DLS spectrum for ZnSe:Mn/ZnS colloidal QDs in chloroform
indicating a reasonably good size distribution with an average hydrodynamic
radius of 10.72 nm .............................................................................................................27
Figure 2.6: Zeta potential distribution for ZnSe:Mn/ZnS QDs in chloroform
showing a peak value of 54.6 mV in the zeta potential distribution curve ........................28
Figure 2.7: Absorption spectrum for ZnSe:Mn/ZnS QDs in chloroform indicating
a small feature around 416 nm wavelength .......................................................................29
Figure 2.8: PL (a) excitation and (b) emission spectra for Zn0.95Mn0.05Se/ZnS
colloidal QDs in chloroform ..............................................................................................31

xi

Figure 2.9: Surface defect PL (a) excitation and (b) emission spectra for
Zn0.95Mn0.05Se/ZnS colloidal QDs in chloroform ..............................................................32
Figure 2.10: (a) and (b) time evolved QE for Mn and surface defect emission,
respectively for ZnSe:Mn/ZnS QDs ..................................................................................33

Figure 3.1: Illustration depicting the bioconjugation process, the assembly of the
QD-based biosensor ...........................................................................................................35
Figure 3.2: Size distribution histograms as generated by dynamic light scattering
(DLS) for Zn0.95Mn0.05Se/ZnS core/shell quantum dots conjugated with (a)
polypeptides containing 9 amino acid residues and (b) polypeptides containing 4
amino acid residues ............................................................................................................37
Figure 3.3: Plot indicating how zeta potential changes with increasing percentage
of cleaved peptides .............................................................................................................38
Figure 3.4: Absorption spectra for substrate and remnant Zn0.95Mn0.05Se/ZnS
QDs in PBS. Both lines exhibit a feature at 257 nm ..........................................................39
Figure 3.5: (a) excitation and (b) emission spectra for Zn0.95Mn0.05Se/ZnS/peptide
colloidal QD conjugates in PBS with the substrate 9 amino acid residue
polypeptide .........................................................................................................................42
Figure 3.6: (a) excitation and (b) emission spectra for Zn0.95Mn0.05Se/ZnS/peptide
colloidal QD conjugates in PBS with the remnant 4 amino acid residue
polypeptide .........................................................................................................................43
Figure 3.7: A plot for determining how much chloroform solvent to use to dilute
3.2 mg/mL of Zn0.95Mn0.05Se/ZnS QDs in chloroform ......................................................48

xii

Figure 3.8: A PL emission intensity vs. percent peptide cleavage plot indicating
that with normalized concentrations intensity still increases as a function of
cleaved peptide percentage ................................................................................................50
Figure 3.9: Quantum efficiency vs. percent peptide cleavage plot indicating that
with normalized concentrations QE also increases as a function of cleaved peptide
percentage ..........................................................................................................................50
Figure 3.10: PLE (a) and PL (b) spectra for substrate peptide coated
ZnSe:Mn/ZnS core/shell QDs in CSF using 600 nm parked emission for PLE and
314 nm parked excitation wavelength for PL ....................................................................51
Figure 3.11: PLE (a) and PL (b) spectra for remnant peptide coated
ZnSe:Mn/ZnS core/shell QDs in CSF................................................................................52

Figure 4.1: MMP-9 activity kinetics at room temperature as measured with the
SensoLyte® 520 MMP - 9 Assay Kit .................................................................................57
Figure 4.2: MMP-9 activity kinetics at 37°C as measured with the SensoLyte®
520 MMP - 9 Assay Kit .....................................................................................................58
Figure 4.3: Fluorometric response of MMP assay Substrate for 1000 ng/mL
MMP9 with increasing temperature from 27.5 ºC to 41.5 ºC ...........................................59
Figure 4.4: QD fluorescence with respect to concentration as read from the Tecan
microplate reader, set on ‘optimal’ gain ............................................................................61
Figure 4.5: Fluorometric responses to varying concentrations of active MMP-9
enzymes from peptide/QD conjugates in water, using the 9 AA peptides, after 2
hours and 20 minutes of incubation ...................................................................................63

xiii

Figure 4.6: Fluorometric responses to varying concentrations of active MMP-9
enzymes from peptide/QD conjugates in artificial CSF, using the +1 charge 9 AA
peptides, after 2 hours and 20 minutes of incubation ........................................................64
Figure 4.7: Results of simultaneous peptide/QD conjugation for (a) conjugates
after being vortexed simultaneously and (b) after washing and dialysis ...........................66
Figure 4.8: Fluorometric responses to varying concentrations of active MMP-9
enzymes from peptide/QD conjugates in CSF, using the 14 AA peptides, after 1
hour of incubation ..............................................................................................................68
Figure 4.9: Fluorometric responses to varying concentrations of active MMP-9
enzymes from peptide/QD conjugates in assay buffer, using the 14 AA peptides,
after 1 hour of incubation ...................................................................................................69
Figure 4.10: Fluorescence based biosensing of MMP9, after 1 hour and 39
minutes of incubation at 37 °C, with varying peptide/QD conjugate concentrations ........71
Figure 4.11: Fluorescence based biosensing of MMP9, after 20 hour and 37
minutes of incubation at 37 °C, with varying peptide/QD conjugate concentrations ........72
Figure 4.12: (a) Excitation and (b) emission spectra for colloidal peptide/QD
conjugates in CSF with 33% substrate polypeptide, using 588 nm and 309 nm for
parked emission and excitation wavelengths, respectively................................................73
Figure 4.13: (a) Excitation and (b) emission spectra for colloidal peptide/QD
conjugates in CSF with 33% remnant polypeptide, using 588 nm and 309 nm for
parked emission and excitation wavelengths, respectively................................................73

xiv

Figure 4.14: (a) Excitation and (b) emission spectra for colloidal peptide/QD
conjugates in CSF with 14-AA 66% substrate polypeptide, using 588 nm and 309
nm for parked emission and excitation wavelengths, respectively ....................................74
Figure 4.15: (a) Excitation and (b) emission spectra for colloidal peptide/QD
conjugates in CSF with 66% remnant polypeptide, using 588 nm and 309 nm for
parked emission and excitation wavelengths, respectively................................................74
Figure 4.16: (a) Excitation and (b) emission spectra for colloidal peptide/QD
conjugates in CSF with 100% 14-AA substrate polypeptide, using 589 nm and
314 nm for parked emission and excitation wavelengths, respectively .............................75
Figure 4.17: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 100% remnant polypeptide, using 596 nm and 317 nm for parked emission
and excitation wavelengths, respectively...........................................................................75
Figure 4.18: Fluorometric response to 1 µg/mL of active MMP-9 in CSF for 66%
peptide/QD conjugates and 33% peptide/QD conjugates ..................................................77
Figure 4.19: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 0.1% 14-AA substrate polypeptide, using 588 nm and 319 nm for parked
emission and excitation wavelengths, respectively ...........................................................78
Figure 4.20: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 0.1% remnant polypeptide, using 588 nm and 319 nm for parked emission
and excitation wavelengths, respectively...........................................................................79
Figure 4.21: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 1% 14-AA substrate polypeptide, using 588 nm and 319 nm for parked
emission and excitation wavelengths, respectively ...........................................................79
xv

Figure 4.22: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 1% remnant polypeptide, using 588 nm and 319 nm for parked emission and
excitation wavelengths, respectively .................................................................................80
Figure 4.23: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 10% 14-AA substrate polypeptide, using 588 nm and 319 nm for parked
emission and excitation wavelengths, respectively ...........................................................80
Figure 4.24: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 10% remnant polypeptide, using 588 nm and 319 nm for parked emission
and excitation wavelengths, respectively...........................................................................81
Figure 4.25: Fluorometric responses to 5 µg/mL of active MMP-9 in CSF for 0.1% ,1%,
and 10% peptide/QD conjugates, after 4 hours of incubation ...........................................82

Figure 5.1: The silane coupling reagent MPTMS and the characteristic
components of a silane coupling agent ..............................................................................84
Figure 5.2: Illustration of the different processes that take place during SCA
modification of silica: (a) hydrolysis, (b) condensation, (c) hydrogen bonding, and
(d) bond formation .............................................................................................................86
Figure 5.3: Illustration of a tethered QD covalently linked to the SH group in
MPTMS modified silica.....................................................................................................87
Figure 5.4: Setup of colloidal QD solution on glass slide in petri dish over
solvent soaked cloth ...........................................................................................................89
Figure 5.5: UV-Vis absorption measurement for ZnSe:Mn/ZnS QDs in toluene
with an absorption feature at ~423 nm ..............................................................................91

xvi

Figure 5.6: UV-Vis absorption measurements for the QD-modified (blue), the
blank (brown), and QD-modified minus the blank slide (black) .......................................91
Figure 5.7: Illustration of the MPTMS coated ZnSe:Mn/ZnS QD nanocomposite ..........92
Figure 5.8: (a) the ZnSe:/Mn/ZnS QD modified silica after baking at 120 °C in
the oven for 30 minutes, (b) the QD modified silica after being thoroughly washed
with chloroform, and (c) a small section of the glass slide cut out for
characterization ..................................................................................................................94
Figure 5.9: (a) PLE and (b) PL spectrum for ZnSe:Mn/ZnS QD modified silica
with 598 nm parked emission for PLE and 380 nm parked excitation for PL...................95
Figure 5.10: Near-IR absorption spectrum for MPTMS (red), MPTMS coated
ZnSe:Mn/ZnS QDs (purple), and supernatant (blue) .........................................................97

Figure 6.1: Macrophage cell viability bar graph depicting the cytotoxic effect of
Mn-doped ZnSe/ZnS peptide coated QD from a six-hour treatment on
macrophage cells ..............................................................................................................104
Figure 6.2: Macrophage cell cytotoxicity bar graph depicting the cytotoxic effect
after a six hours treatment of Mn-doped ZnSe/ZnS peptide coated QDs on
macrophage cells in cell media ........................................................................................105
Figure 6.3: Macrophage cell induced apoptosis bar graph depicting induced
apoptosis after a six-hour treatment of Mn-doped ZnSe/ZnS peptide coated QDs
on macrophage cells in cell media ...................................................................................106

xvii

Figure 6.4: Macrophage cell viability bar graph depicting the cytotoxic effect of
Mn-doped ZnSe/ZnS peptide coated QD from a twelve-hour treatment on
macrophage cells ..............................................................................................................107
Figure 6.5: Macrophage cell viability bar graph depicting the cytotoxic effect of
Mn-doped ZnSe/ZnS peptide coated QD from a twelve-hour treatment on
macrophage cells ..............................................................................................................109
Figure 6.6: Macrophage cell induced apoptosis bar graph depicting induced
apoptosis after a twelve-hour treatment of Mn-doped ZnSe/ZnS peptide coated
QDs on macrophage cells in cell media ...........................................................................110
Figure 6.7: Macrophage cell viability bar graph depicting the cytotoxic effect of
Mn-doped ZnSe/ZnS peptide coated QD from a twenty-four hour treatment on
macrophage cells ..............................................................................................................111
Figure 6.8: Macrophage cell viability bar graph depicting the cytotoxic effect of
Mn-doped ZnSe/ZnS peptide coated QD from a twenty-four twelve-hour
treatment on macrophage cells.........................................................................................112
Figure 6.9: Macrophage cell induced apoptosis bar graph depicting induced
apoptosis after a twenty-four hour treatment of Mn-doped ZnSe/ZnS peptide
coated QDs on macrophage cells in cell media ...............................................................114
Figure 6.10: Macrophage cell viability bar graph depicting the cytotoxic effect
after a forty-eight hours treatment of Mn-doped ZnSe/ZnS peptide coated QDs on
macrophage cells in cell media ........................................................................................115

xviii

Figure 6.11: Macrophage cell cytotoxicity bar graph depicting the cytotoxic
effect of Mn-doped ZnSe/ZnS peptide coated QD from a forty-eight hour
treatment on macrophage cells.........................................................................................116
Figure 6.12: Macrophage cell induced apoptosis bar graph depicting induced
apoptosis after a forty-eight six-hour treatment of Mn-doped ZnSe/ZnS peptide
coated QDs on macrophage cells in cell media ...............................................................117

xix

List of Tables

Page

Table 1.1: List of several pathological and physiological processes MMPs play a
role in ...................................................................................................................................3

xx

List of Publications
1. K. Sankar, J. B. Plumley, B. A. Akins, T. A. Memon, N. J. Withers, G. A. Smolyakov,
and M. Osiński, “Synthesis and characterization of scintillating cerium-doped
lanthanum fluoride nanocrystals”, Colloidal Quantum Dots for Biomedical
Applications IV (M. Osiński, T. M. Jovin, and K. Yamamoto, Eds.), SPIE
International Symposium on Biomedical Optics BiOS 2009, San Jose, California,
24-26 January 2009, Proceedings of SPIE, Vol. 7189, Paper 718909 (12 pp.).
2. N. J. Withers, J. B. Plumley, N. D. Triño, K. Sankar, B. A. Akins, A. C. Rivera, G. A.
Smolyakov, G. S. Timmins, and M. Osiński, “Scintillating-nanoparticle-induced
enhancement of absorbed radiation dose”, Colloidal Quantum Dots for
Biomedical Applications IV (M. Osiński, T. M. Jovin, and K. Yamamoto, Eds.),
SPIE International Symposium on Biomedical Optics BiOS 2009, San Jose,
California, 24-26 January 2009, Proceedings of SPIE, Vol. 7189, Paper 718917 (8
pp.).
3. N. J. Withers, B. A. Akins, A. C. Rivera, J. B. Plumley, G. A. Smolyakov, and M.
Osiński,
“Lead-iodide based nanoscintillators for detection of ionizing
radiation”,
Chemical, Biological, Radiological, Nuclear, and Explosives
(CBRNE) Sensing X (A. W. Fountain, III and P. J. Gardner, Eds.), SPIE Defense,
Security, and Sensing Symposium, Orlando, Florida, 14-16 April 2009,
Proceedings of SPIE, Vol. 7304, Paper 73041N (12 pp.).
4. M. Osiński, K. Sankar, N. J. Withers, J. B. Plumley, A. C. Rivera, B. A. Akins, and G.
A. Smolyakov,
“Lanthanide-halide-based nanoscintillators for portable
radiological detectors (Invited Paper)”, Optics and Photonics in Global
Homeland Security V and Biometric Technology for Human Identification VI (C.
S. Halvorson, Š. O. Southern, B. V. K. V. Kumar, S. Prabhakar, and A. A. Ross,
Eds.), SPIE Defense, Security, and Sensing Symposium, Orlando, Florida, 13-16
April 2009, Proceedings of SPIE, Vol. 7306, Paper 730617 (16 pp.).
5. N. J. Withers, K. Sankar, J. B. Plumley, B. A. Akins, T. A. Memon, A. C. Rivera, G.
A. Smolyakov, and M. Osiński, “Optimization of Ce content in CexLa1-xF3
colloidal nanocrystals for gamma radiation detection”, Nuclear Radiation
Detection Materials – 2009 (D. L. Perry, A. Burger, L. Franks, K. Yasuda, and M.
Fiederle, Eds.), 2009 MRS Spring Meeting, San Francisco, California, 13-17
April 2009, MRS Symposium Proceedings, Vol. 1164, Paper L07-02 (6 pp.).
6. N. J. Withers, J. B. Plumley, B. A. Akins, G. Medina, G. Timmins, G. A. Smolyakov,
and M. Osiński, “Radiation sensitivity enhancement in cells using high-Z
nanoparticles”,
accepted for Colloidal Quantum Dots for Biomedical
Applications V (M. Osiński, W. J. Parak, T. M. Jovin, and K. Yamamoto, Eds.),
SPIE International Symposium on Biomedical Optics BiOS 2010, San Francisco,
California, 23-25 January 2010, Proceedings of SPIE, Vol. 7575, Paper 7575-33.

xxi

7. M. Osiński, J. B. Plumley, N. J. Withers, B. A. Akins, G. Medina, A. C. Rivera, and G.
A. Smolyakov, “Synthesis and characterization of lanthanide halide scintillating
nanocrystals for gamma radiation detection”, Symposium 2. Nanomaterials,
2010 International Conference on Nanoscience and Nanotechnology ICONN
2010, Sydney, Australia, 22-26 February 2010 (4 pp.)
8. J. B. Plumley, N. J. Withers, A. C. Rivera, B. A. Akins, J. M. Vargas, K. Carpenter, G.
A. Smolyakov, R. D. Busch, and M. Osiński, “Thermal neutron detectors based
on gadolinium-containing lanthanide-halide nanoscintillators”,
Chemical,
Biological, Radiological, Nuclear, and Explosives (CBRNE) Sensing XI (A. W.
Fountain, III and P. J. Gardner, Eds.), SPIE Defense, Security, and Sensing
Symposium, Orlando, Florida, 6-8 April 2010, Proceedings of SPIE, Vol. 7665,
Paper 76651F (13 pp.).
9. N. J. Withers, N. N. Glazener, J. B. Plumley, B. A. Akins, A. C. Rivera, N. C. Cook,
G. A. Smolyakov, G. S. Timmins, and M. Osiński, “Locally increased mortality
of gamma-irradiated cells in presence of lanthanide-halide nanoparticles”,
Colloidal Quantum Dots/Nanocrystals for Biomedical Applications VI (W. J.
Parak, K. Yamamoto, and M. Osiński, Eds.), SPIE International Symposium on
Biomedical Optics BiOS 2011, San Francisco, California, 22-24 January 2011,
Proceedings of SPIE, Vol. 7909, Paper 7909-0L (12 pp.).
10. M. Osiński, Y. Brandt, J. M. Vargas, J. B. Plumley, S. R. Maestas, A. C. Rivera, N.
C. Cook, N. J. Withers, G. A. Smolyakov, N. L. Adolphi, S. L. McGill, I. ElSherbiny, and H. D. C. Smyth, “Multifunctional nanoparticles for lung delivery
of drugs (Invited Paper)”, Fifth International Conference on Advanced Materials
and Nanotechnology AMN-5, Wellington, New Zealand, 7-11 February 2011.
11. J. M. Vargas, A. A. McBride, J. B. Plumley, Y. Fichou, T. A. Memon, V. Shah, N.
Cook, B. A. Akins, A. C. Rivera, G. A. Smolyakov, J. R. O'Brien, N. L. Adolphi,
H. D. C. Smyth, and M. Osiński, “Synthesis and characterization of core/shell
Fe3O4/ZnSe fluorescent magnetic nanoparticles”, Journal of Applied Physics 109
(#7), Art. 07B536 (3 pp.), April 2011.
12. A. C. Rivera, N. N. Glazener, N. C. Cook, B. A. Akins, J. B. Plumley, N. J. Withers,
K. Carpenter, G. A. Smolyakov, R. D. Busch, and M. Osiński, “Detection of
thermal neutrons using gadolinium-oxide-based nanocrystals”,
Chemical,
Biological, Radiological, Nuclear, and Explosives (CBRNE) Sensing XII (A. W.
Fountain, III and P. J. Gardner, Eds.), SPIE Defense, Security, and Sensing
Symposium, Orlando, Florida, 25-29 April 2011, Proceedings of SPIE, Vol.
8018, Paper 80180F (12 pp.).
13. A. C. Rivera, N. C. Cook, N. N. Glazener, N. J. Withers, J. B. Plumley, B. A. Akins,
G. A. Smolyakov, R. D. Busch, and M. Osiński, “Dysprosium-containing
nanocrystals for thermal neutron detection”, Symposium U, Nuclear Radiation
Detection Materials (A. Burger, M. Fiederle, L. Franks, K. Lynn, D. L. Perry, and
xxii

K. Yasuda, Eds.), 2011 MRS Spring Meeting, San Francisco, CA, 26-28 April
2011, MRS Proceedings, Vol. 1341, Paper U9.2 (6 pp.)
14. M. Osiński, B. A. Akins, J. B. Plumley, A. C. Rivera, N. C. Cook, A. Agarwal, and
G. A. Smolyakov, “High-temperature nanophosphors for white-light-emitting
diodes (Invited Paper)”,
Proceedings of the 16th Opto-Electronics and
Communications Conference OECC 2011, Kaohsiung, Taiwan, 4-8 July 2011 (4
pp.).
15. M. Osiński, L. M. Armijo, Y. Brandt, S. R. Maestas, A. C. Rivera, N. C. Cook, J. B.
Plumley, B. A. Akins, G. A. Smolyakov, N. L. Adolphi, D. L. Huber, S. L.
McGill, L. Gong, and H. D. C. Smyth, “Multifunctional nanoparticles for drug
delivery in cystic fibrosis (Invited Paper)”, Zing Nanomaterials Conference,
Xcaret, Quintana Roo, Mexico, 28 November – 2 December 2011.
16. A. C. Rivera, N. N. Glazener, N. C. Cook, L. M. Armijo, J. B. Plumley, B. A. Akins,
K. Carpenter, G. A. Smolyakov, R. D. Busch, and M. Osiński, “Dysprosiumcontaining nanocrystals for use as a neutron detector in a solvent suspension”,
Zing Nanomaterials Conference, Xcaret, Quintana Roo, Mexico, 28 November –
2 December 2011.
17. L. M. Armijo, Y. Brandt, D. L. Huber, N. J. Withers, J. B. Plumley, N. C. Cook, A.
C. Rivera, G. A. Smolyakov, S. Yadav, H. D. C. Smyth, and M. Osiński,
“Multifunctional superparamagnetic nanocrystals for imaging and targeted drug
delivery to the lung”, accepted for Colloidal Quantum Dots/Nanocrystals for
Biomedical Applications VII (W. J. Parak, M. Osiński, and K. Yamamoto, Eds.),
SPIE International Symposium on Biomedical Optics BiOS 2012, San Francisco,
California, 21-23 January 2012, Proceedings of SPIE, Vol. 8232, Paper 22.
18. M. Osiński, L. M. Armijo, Y. Brandt, S. R. Maestas, A. C. Rivera, N. C. Cook, J. B.
Plumley, B. A. Akins, G. A. Smolyakov, N. L. Adolphi, L. Gong, and H. D. C.
Smyth, , “Multifunctional superparamagnetic nanoparticles for drug delivery in
cystic fibrosis (Invited Paper)”, International Conference and Workshop on
Nanostructured Ceramics and Nanomaterials ICWNCN-12, New Delhi, India,
13-16 March 2012.
19. A. C. Rivera, N. N. Glazener, N. C. Cook, S. Maestas, B. A. Akins, L. M. Armijo, J.
B. Plumley, N. J. Withers, K. Carpenter, G. A. Smolyakov, R. D. Busch, and M.
Osiński, “Thermal neutron detection with PMMA nanocomposites containing
dysprosium fluoride nanocrystals”,
accepted for Chemical, Biological,
Radiological, Nuclear, and Explosives (CBRNE) Sensing XIII, SPIE Defense,
Security, and Sensing Symposium, Baltimore, Maryland, 23-27 April 2012,
Paper 8358-66.
20. B. A. Akins, A. C. Rivera, J. B. Plumley, N. C. Cook, S. A. Ivanov, G. A.
Smolyakov, and M. Osiński, “Cadmium-free ZnSe:Mn/ZnS high temperature
xxiii

nanophosphors with record high quantum efficiency for white LED applications”,
Technical Digest, 7th International Conference on Quantum Dots, Santa Fe, New
Mexico, 13-18 May 2012, Paper Th-72.
21. N. C. Cook, A. C. Rivera, N. N. Glazener, B. A. Akins, L. M. Armijo, J. B. Plumley,
N. J. Withers, K. Carpenter, G. A. Smolyakov, R. D. Busch, and M. Osiński,
“Polyvinyl toluene/Gd2O3:10%Ce scintillating nanocomposites for thermal
neutron detection”, Technical Digest, 7th International Conference on Quantum
Dots, Santa Fe, New Mexico, 13-18 May 2012, Paper Th-73.
22. A. C. Rivera, N. N. Glazener, N. C. Cook, S. R. Maestas, B. A. Akins, L. M. Armijo,
J. B. Plumley, N. J. Withers, K. Carpenter, G. A. Smolyakov, R. D. Busch, and
M. Osiński, “Thermal neutron detection with Gd2O3:10%Ce nanocrystals loaded
into a polyvinyl toluene matrix”, IEEE Symposium on Radiation Measurements
and Applications SORMA WEST 2012, Oakland, California, 14-17 May 2012.
23. L. M. Armijo, B. A. Akins, J. B. Plumley, A. C. Rivera, N. J. Withers, N. C. Cook, G.
A. Smolyakov, D. L. Huber, H. D. C. Smyth, and M. Osiński, “Highly efficient
multifunctional MnSe/ZnSeS quantum dots for biomedical applications”,
Colloidal Nanoparticles for Biomedical Applications VIII (W. J. Parak, M.
Osiński, and K. Yamamoto, Eds.), SPIE International Symposium on Biomedical
Optics BiOS 2013, San Francisco, California, 2-4 February 2013, Proceedings of
SPIE, Vol. 8595, Paper 859517 (7 pp.).
24. N. J. Withers, N. N. Glazener, A. C. Rivera, B. A. Akins, L. M. Armijo, J. B.
Plumley, N. C. Cook, J. M. Sugar, R. Chan, Y. I. Brandt, G. A. Smolyakov, P. H.
Heintz, and M. Osiński, “Effects of La0.2Ce0.6Eu0.2F3 nanocrystals capped with
polyethylene glycol on human pancreatic cancer cells in vitro”, Colloidal
Nanoparticles for Biomedical Applications VIII (W. J. Parak, M. Osiński, and K.
Yamamoto, Eds.), SPIE International Symposium on Biomedical Optics BiOS
2013, San Francisco, California, 2-4 February 2013, Proceedings of SPIE, Vol.
8595, Paper 85951O (9 pp.).
25. M. Osiński, J. B. Plumley, B. A. Akins, N. J. Withers, Y. I. Brandt, and E. D.
Milligan, “Quantum-dot-based biosensor of matrix metalloproteinase activity
(Invited Paper)”, Proceedings of 2nd International Conference and Exhibition on
Biosensors and Bioelectronics, Chicago, Illinois, 17-19 June 2013, Journal of
Biosensors and Bioelectronics, vol. 4, no. 3, p. 41, June 2013.
26. B. A. Akins, S. A. Ivanov, J. B. Plumley, S. M. Stephens, N. C. Cook, G. A.
Smolyakov, and M. Osiński, “High-temperature ZnSe:Mn/ZnS nanophosphors
with very high quantum efficiency for white LEDs”, Technical Digest, Tenth
Conference on Lasers and Electro-Optics Pacific Rim CLEO-PR 2013, Kyoto,
Japan, 30 June – 4 July 2013, Paper ThI3-7 (2 pp.).

xxiv

27. L. M. Armijo, M. Kopciuch, B. A. Akins, J. B. Plumley, N. J. Withers, A. C. Rivera,
N. C. Cook, Y. I. Brandt, J. M. Baca, S. J. Wawrzyniec, G. A. Smolyakov, D. L.
Huber, and M. Osiński, “Low-toxicity magnetic nanomaterials for biomedical
applications”, accepted for 21st Annual International Conference on Composites
/ Nano Engineering ICCE-21, Tenerife, Spain, July 21-27, 2013.
28. N. N. Glazener, A. C. Rivera, N. C. Cook, S. R. Maestas, B. A. Akins, L. M. Armijo,
J. B. Plumley, N. J. Withers, K. Carpenter, G. A. Smolyakov, R. D. Busch, and
M. Osiński, “Thermal neutron detection with Gd2O3:10%Ce nanocrystals loaded
into a polyvinyl toluene matrix”,
submitted to Beilstein Journal of
Nanotechnology.
29. J. B. Plumley, B. A. Akins, G. J. Alas, M. E. Fetrow, J. Nguyen, P. Jain, S. Yang, Y.
I. Brandt, G. A. Smolyakov, W. Ornatowski, E. D. Milligan, and M. Osiński,
“Noncytotoxic Mn-doped ZnSe/ZnS quantum dots for biomedical applications”,
accepted for Colloidal Nanocrystals for Biomedical Applications IX (W. J. Parak,
M. Osiński, and K. Yamamoto, Eds.), SPIE International Symposium on
Biomedical Optics BiOS 2014, San Francisco, California, 01 February 2014,
Proceedings of SPIE, Vol. 8955.
30. L. M. Armijo, M. Kopciuch, Z Olszówka, S. J. Wawrzyniec, A.C. Rivera, J. B.
Plumley, N. C. Cook, Y. I. Brandt, D. L. Huber, G. A. Smolyakov, N. L. Adolphi,
H. D. C. Smyth, and M. Osiński, “Delivery of tobramycin coupled to iron oxide
nanoparticles across the biofilm of mucoidal Pseudonomas aeruginosa and
investigation of its efficacy”, accepted for Colloidal Quantum Dots/Nanocrystals
for Biomedical Applications IX (W. J. Parak, M. Osiński, and K. Yamamoto,
Eds.), SPIE International Symposium on Biomedical Optics BiOS 2014, San
Francisco, California, 01 February 2014, Proceedings of SPIE, Vol. 8955.
31. A.C. Rivera, N. N. Glazener, N. C. Cook, B. A. Akins, L. M. Armijo, J. B. Plumley,
N. J. Withers, K. Carpenter, G. A. Smolyakov, R. D. Busch, and M. Osiński,
“Characterisation of potassium bromide loaded with dysprosium fluoride
nanocrystals for neutron detection”, International Journal of Nanotechnology 11
(#5), 529-538, April 21, 2014.
32. J. B. Plumley, B. Akins, G. J. Alas, M. E. Fetrow, J. Nguyen, P. Jain, S. Yang, Y.
Brandt, G. Smolyakov, W. Ornatowski, E. D. Milligan, M. Osiński’ “In vitro
Cytotoxicity of peptide coated Mn-doped ZnSe/ZnS quantum dots on macrophage
cells”, Journal of Bionanotechnology, pending submission.

xxv

Patent applications
1. M. Osiński, J. B. Plumley, G. A. Smolyakov, N. J. Withers, A. C. Rivera, B. A. Akins,
and J. M. Vargas, “Thermal neutron detectors based on gadolinium-containing
nanoscintillators”, United States Provisional Patent Application 61/473,071 filed
on 7 April 2011.
2. J. B. Plumley, A. D. Milligan, and M. Osiński, “Amyotrophic lateral sclerosis
detection devices, methods, and biomarkers”, United States Provisional Patent
Application filed on 5 December 2011.

xxvi

Chapter 1
Introduction to matrix metalloproteinase, quantum dots, and quantum dot-based
biosensing
1.1 Matrix metalloproteinase (MMPs) and their potential as biomarkers
MMPs are enzymes which consist of a vast family of zinc-dependent
endopeptidases that can bind to non-terminal amino acids in peptides and catalyze
hydrolysis, splitting the peptide substrate into two separate molecules (cleaving). MMP
types are differentiated based on their size and the specific substrates they interact with.
So far, at least 26 different types of human MMPs have been identified1. They are
responsible for tissue repair and break down of the extracellular matrix. Abnormal MMP
activity can be indicative of many different pathological disorders. On one hand, MMPs
partake in a large number of physiological processes such as tissue repair, immune
system activation, inflammation, apoptosis, etc. On the other hand, their abnormal
activity is associated with many different pathological conditions, such as cancer,
arthritis, central nervous system (CNS) disorders, and so on.
MMPs are initially synthesized as inactive, but become active due to injury,
inflammation, or the presence of other proteinases, foreign bodies, and pathogens. Figure
1.1 is a diagram depicting MMP activation in the presence of reactive oxygen species or
the presences of other MMPs or proteinases2. In specific, MMPS are made active by the
removal of a peptide blocking the active region due to a bond between the Zn ion and the
thiol group in the cysteine amino acid residue.
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Figure 1.1: Diagram depicting the activation of a MMP-2 enzyme by being
converted from its pro-inactive form to its pro-active form through reactive
oxygen species and its active form from additional proteinase activity2.

The ubiquitous presence of MMPs in a large number of pathological conditions
offers an attractive new way of early detection of these conditions through biosensing of
MMP activity at specific sites. For example, biosensors placed at pain signaling sites
could be used for detection of neuropathic pain. However, at present no sensors exist
capable of real-time in vivo reporting of MMP activity. (Table 1.1) illustrates numerous
processes, pathological and physiological, that MMPs play a role in.

2

Table 1.1: List of several pathological and
physiological processes MMPs play a role in1.

Currently, there are no biomarkers for neuropathic pain, and yet it is important to
objectively identify patients in need of treatment. Targeting non-neuronal signaling
mechanisms could lead to a novel biomarker for identifying neuropathic pain. Spinal cord
glia contribute to chronic pathological pain by responding to and releasing
proinflammatory cytokines and MMPs3. Identifying MMP-based biomarkers for
neuropathic pain has the potential to yield a better understanding of the mechanisms
behind pain processing and a way of objectively characterizing pain, therefore
contributing to treatment development. Existing pain treatments that target neurons are
not very effective, because pain is only reduced by 25-40% in less than half of the 15
million patients in the US that suffer from chronic neuropathic pain4. The present lack of
effective therapeutic agents is largely due to a poor understanding of the mechanisms that
3

underlie neuropathic pain3. It can be expected that with the identification of
pathophysiological mechanisms that contribute to pain, new and improved neuropathic
pain treatments can be developed5.
Consequently, there has been an increasing interest in studying MMP enzyme
expression in neuropathic pain. Several studies on MMP activity in traumatic nerve injury
generally indicate modulations in MMP expression in the CNS. In particular, MMP-9 is
rapidly upregulated and induces pain initially upon nerve injury, while the response of
MMP-2 is delayed and induces pain at a later time6. Also, in the case of lumbar disc
herniation that leads to chronic pain, MMP-1 and MMP-3 expression is correlated to the
age of patients as well as the degree of disc herniation7. Most of these studies were done
using multistep endpoint assay processes, such as gel electrophoresis (gelatin
zymography), enzyme-linked immunosorbent assay (ELISA), or immunohistochemical
(IHC) staining. A simple and highly effective sensing method for indicating these
findings at pain-processing sites could have a tremendous impact on how we study the
mechanisms underlying neuropathic pain, such as being able to monitor and quantify
MMP modulations in real time in the direct vicinity of nerve lesions.
Additionally, MMP-based biomarkers have the potential for early diagnosis of
CNS disorders, in particular amyotrophic lateral sclerosis (ALS). ALS is a progressive
neurodegenerative disease in which motor neurons degrade and can no longer transmit
signals to muscles and is ultimately fatal. Symptoms of the disease include progressive
weakening of muscles, muscle spasms, and muscle atrophy. 100,000 people suffer from
the disease worldwide8, with patients dying from respiratory failure usually 3-5 years
after being diagnosed9. 10% of ALS cases are due to genetic defects while the other 90%
4

are sporadic with unknown causes. Currently there is no cure for ALS and as it stands
there is no definitive diagnostic test for ALS. The current way to diagnose ALS involves
a series of physical examination tests as well as additional tests to rule out other diseases
with ALS like symptoms, such as HIV and Lyme disease9. In order to diagnose someone
with ALS, a physician will have to evaluate a patient suffering from ALS like symptoms
at regular intervals in order to determine if these symptoms are getting progressively
worse. The symptom evaluation is supplemented with a series of test such as MRI,
blood, and urine test in order to rule out other diseases or causes for ALS like symptoms
in a patient. Because of the lengthy diagnostic testing, it is reasonable to believe that
patients are not diagnosed with ALS in the early stages of the disease.
A reliable ALS biomarker will enable earlier diagnosis which will contribute to
treatment development for ALS. Earlier diagnosis will aid treatment development
because future treatments will more likely be efficacious in the early stages of disease
development10.
There has been an increasing interest in MMP activity as a biomarker for other
CNS disorders and diseases, as well. There have been several studies on MMP activity in
patients with neurological diseases with the results generally indicating abnormal MMP
activity in the serum and CSF. In specific, patients with ALS statistically show 3 times
lower MMP-9 activity in the CSF and 2 time higher MMP-9 activity in the serum in
comparison to healthy controls by using gel zymography testing11. Furthermore, it was
statistically shown that patients with HIV12 and multiple sclerosis13 have increased MMP9 activity while patients with Alzheimer’s show no abnormal MMP-9 activity at all14.
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MMPs also play a necessary role in wound healing, in that they regulate tissue
reformation and are highly expressed at the site of a wound. With at least 10 different
types of MMPs being upregulated during the skin healing process in mammals15, being
able to quantitatively probe the involvement of MMPs in situ would be attractive. This is
mainly because in order to optimally care for and treat a chronic wound an understanding
of the role that the ECM plays in healing is required16.

1.2 Colloidal quantum dots and their merits
Luminescent semiconductor nanocrystals, also known as quantum dots (QDs),
have been on the frontier of scientific research for the past few decades. Colloidal QDs
are traditionally composed of a CdSe core and a ZnS shell, which acts as a passivation
layer that enhances optical properties. CdSe/ZnS QDs are synthesized colloidally at high
temperatures, and their size and shape can be controlled from synthesis conditions such
as temperature, solvent, and surfactant. The fluorescence of CdSe/ZnS QDs is tunable
based on their size, resulting in the unique characteristic that different batches of
CdSe/ZnS QDs can appear to have different emission colours. When the semiconductor
material becomes smaller than its exciton Bohr radius, which is typically less than 10 nm,
quantum confinement is achieved, and band gap energies become a function of QD size.
These band gap energies scale inversely with QD size, meaning band gap energies
increase as the size of QDs become smaller. The effect is that as QDs get smaller their
emission color shifts from red to blue (Figure 1.2a). Also, QDs have broad spectroscopic
absorption bands and narrow emission lines (Figure 1.2b) with the primary benefit being
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that with a single excitation wavelength multiple QD emissions can be excited with good
resolution at the same time.

(b)

(a)

Figure 1.2: (a) Size tunable fluorescence emission from multiple colloidal solutions of
CdSe/ZnS QDs and (b) excitation/emission spectra illustrating the narrow emission and
broad absorption19. Under the same excitation wavelength, the fluorescence shifts along
the visible spectrum from red to blue as the size of the QDs decreases. The CdSe/ZnS
nanocomposite material undergoes an increase in bandgap energy as its size decreases.

The number of inherent advantages of QDs over traditional fluorophores, which
includes high photoluminescence intensity, high quantum efficiency, high stability, high
surface to volume ratio, and narrow emission spectra with broad absorption spectra,
contribute to their beneficial use as optical detectors that are compatible with biological
processes in the human body17, 18. Further advantages include resistance to
photobleaching, broad absorption spectra (with 10-50 times larger molar extinction
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coefficients), and high efficiency for applications involving Forster resonance energy
transfer (FRET), due to multiple binding sites of energy acceptors19.
Due to their bright and stable fluorescence properties, colloidal quantum dots
(QDs) may be suitable for complex in vivo conditions20. QDs have 10-20 times larger
absorption coefficients than conventional dyes which results in more efficient probe
excitation under in vivo conditions where light scatter is greatly reduced21. In addition,
the large Stokes shift of QDs helps to eliminate self-absorption and allows the target
fluorescence signal to be more clearly separated from the excitation light.
Also, traditional fluorophores have limitations in multicolor detection
applications, due to their broad and overlapping emission lines and relatively narrow
excitation bands22. In contrast, QD fluorophores can have narrow emission and broad
absorption lines, resulting in the ability to efficiently excite multiple emission colors with
a single excitation source. Commercial CdSe/ZnS QDs are not, however, acceptable for
any in vivo applications due to high toxicity of Cd. Replacing the Cd component with Zn
as in the case of Mn-doped ZnSe QDs is speculated to be a less toxic alternative to CdSe
and is a primary topic explored in this dissertation.

1.3 QD-based MMP biosensing
Biosensors utilize biorecognition strategies as a way of detecting, in real time, the
presence or activity of specific biomolecules of interest. A biosensor consists of a
biorecognition element such as antibodies, DNA, peptides, and enzymes, which
recognizes and interacts/binds with an analyte. A biosensor also consists of a transducer
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element, which is responsible for transforming an optical or electrical signal into a
quantifiable measurement upon detection of the analyte. Biosensors have numerous
applications in the field of biomarkers and diagnostics.
MMP biosensors are commercially available and consist of an ensemble of
peptide sensing elements encoded to have a motif specific for a particular MMP of
interest, in buffer solution. The peptide, generally less than 10 nm long, will have a FRET
acceptor on one side and a FRET donor on another side. The absorption wavelength
range of the acceptor overlaps the emission wavelength range of the donor, and therefore
the acceptor will quench the fluorescent emission from the donor. However, when an
MMP cleaves the peptide sensing element, the donor and acceptor are no longer in the
direct vicinity of one another and the fluorescence of the donor is restored, resulting in a
quantifiable fluorescent signal that can be correlated to the concentration of active
MMPs.
A QD can act as a FRET donor and multiple biomolecules that can act as FRET
acceptors can be conjugated to the QD surface (Figure 1.3), resulting in an increase in
FRET efficiency19.
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Figure 1.3: Illustration of a single CdSe/ZnS QD bioconjugate containing an inorganic
CdSe core, an inorganic ZnS shell, an organic polymer coating such as PEG, and an
outer layer of biomolecules such as antibodies, peptides, streptavidin, DNA, etc19. For
FRET based biosensing, the fluorescent inorganic core/shell works as a donor, and
because of the high surface area to volume ratio, multiple acceptors can be conjugated
around the surface increasing FRET efficiency.
As a result of the considerable amount of multiplicity and substrate overlap with
the different types of MMPs, there is a redundancy in the functioning of MMPs23. With
the possibility to coat QDs with substrates for different MMP types, such as collagen,
gelatin, or peptides, experiments with multiplexing capabilities are possible, which could
better resolve the involvement of the different types of MMPs in pathological conditions.
The long term goal of this research is development of a novel functionalized Cdfree nanomaterial interface by means of self-assembly and bioconjugation strategies that
ultimately would be capable of in vivo real-time fluorometric biosensing of matrix
metalloproteinase (MMP) activity. The successful development of said biosensor is
expected to have a great potential for novel applications that will benefit from
determination of concentrations of various MMPs, such as characterizing aberrant pain
processing at the spinal level during peripheral neuropathic conditions, monitoring and
10

control of wound healing process, detection of early signs of cancer, early diagnosis of
CNS disorders such as ALS, etc.
This biosensing method would be capable of in situ studies for MMPs during
wound healing. The current method used to study MMP activity at the site of a wound
involves immunohistochemistry (IHC), in which fluorescently tagged antibodies can be
used to visualize the MMP expression; however, IHC is primarily a qualitative analysis24
and the inclusion of a biosensing method capable of quantitative analysis to supplement
in situ IHC observations would be beneficial.
However, MMPs are thought to be implicated in the pathogenesis of other
neurological diseases as well, and it is imperative that MMP activity be fully understood
and characterized to the point that it can be a reliable biomarker. This may require a
highly sensitive method that measures MMP activity directly at the site of motor neuron
degradation in the CSF in vivo.
An essential feature of an in vivo QD-based biosensor is that it will utilize highly
efficient Cd-free ZnSe/ZnS QDs that are not expected to display any cytotoxicity.
Equally important is the fact that the QDs will be tethered to an optical fiber tip and at no
point will be released into the body, thus avoiding the issue of how the QDs are
metabolized, where they could end up accumulating, and what could be their long-term
effects.
Real-time in vivo biosensing of MMP activity is at this stage completely
unexplored. Enzyme activity is very temperature- and environment- dependent and so
performing experiments under in vitro conditions, where lab environment is not the same
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as the local environment of the enzymes inside the body, may be distorting the actual
kinetics of MMP activity. Measuring the activity outside of the body, as in an in vitro
procedure, would diminish the enzyme activity due to a decrease in temperature25. By
utilizing the proposed in vivo biosensor, it will be possible to explore the actual kinetics
of MMP activity beyond what can be achieved with multi-step assay processes or in vitro
biosensing.
The bio-interface of the intended biosensor would be peptides bioconjugated to
QDs tethered to the silica tip of an optical fiber. By tethering the QDs to the fiber, no
QDs would be released into the biosensing site, i.e. into the body, while in vivo
measurements are being made. The transducer component of the biosensor will be based
on measurable perturbations in QD fluorescence that could result from MMP interaction
with the bioconjugated peptides. In order to develop a calibration curve, MMP activity
sensing measurements will first need to be made in different known concentrations of
MMPs in solution.
The two MMPs that have been so far studied much more extensively than the
remaining MMPs are MMP-2 and MMP-9. Therefore, for this biosensing research the
target molecules will be the MMP-2 and MMP-9 enzymes. It should be emphasized,
however, that the proposed concept is very general, and numerous MMPs can be targeted.
Also, multiplexing for different proteinase enzymes on the same fiber tip is feasible. The
biorecognition mechanism will be based on enzyme substrate selectivity with a peptide of
an amino acid sequence that the target MMP selectively binds to. In the case of MMP-9,
the substrate peptide includes the motif Val-Val-Pro-Leu-Ser—Leu-Arg-Ser26, with the
MMP-9 enzyme catalyzing hydrolysis of the bond between Ser and Leu amino acid
12

residues, which results in a cleaved peptide. Peptides of the MMP-9 substrate sequence
will be bioconjugated to the surface of QDs, with the intention of using the modified QDs
to measure MMP-9 activity from observable changes that can occur in the fluorescence
of the QDs when the peptides are cleaved. From the magnitude of perturbation in the QD
fluorescence that takes place, a quantitative analysis of MMP-9 activity can be made.
The QDs will be immobilized onto the silica surface, via the use of the silane
coupling reagent, 3-mercaptopropyltrimethoxysilane (MPTMS), which contains a thiol
functional group that covalently binds to metallic surfaces, due to a known affinity
between thiol molecules and metal. Hydrolyzable regions of MPTMS react with hydroxyl
groups on hydroxyl modified silica and form stable oxane bonds acting as a linker
molecule for covalently bonding QDs to silica.
The optical setup for the biosensor will consist of a diode laser excitation source
coupled to a fiber, a Y-fiber (fiber coupler) for dual entrance and exit of the excitation
and emission light respectively, and a spectrometer with an array detector at the output
end (Fig. 4.1).
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Figure 1.4: Biosensor setup illustrating the approach to utilizing QD-modified optical
fibers to quantify MMP activity by exciting the QDs with light through one input of the
fiber coupler and subsequently measuring light emission at the output by a detector array
at the output of a spectrometer.

A number of different peptide motifs have been identified for different types of
MMPs. The specific motif for MMP-9 is Val-Val-Pro-Leu-Ser---Leu-Arg-Ser, where the
MMP-9 enzyme binds between serine and leucine and catalyzes hydrolysis, and the
resulting effect is that of a protein cleaved in two, creating a new C and N-terminus.
Interestingly enough, a recent finding shows that conjugating the MMP-9 peptide
substrate to Zn0.95Mn0.05Se/ZnS QDs results in the quantum efficiency of the sample
dropping significantly between the QD and QD-conjugates. Most remarkable is that when
the cleaved (enzyme digested) peptide that only contains four amino acids is conjugated
to same Zn0.95Mn0.05Se/ZnS QDs at the same QD to peptide ratio as the 9-amino acid
polypeptide, the QE drops a lot less dramatically, twenty times less. The change in QE
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between the substrate and remnant peptide/QD bioconjugates serves as the basis for the
biosensing concept and is illustrated in Figure 1.5.

Figure 1.5: Illustration of QD fluorescence (a) before and (b) after the surface
peptide is cleaved.
It is anticipated that when the MMP-9 enzymes cleave the polypeptide a dequenching effect will take place of which the intensity can be used to quantify MMP-9
activity. Also, because different peptide motifs for different types of MMPs can be
conjugated to QDs with different fluorescence emission wavelengths the biosensor is
multiplexing capable, which provides the most powerful tool for diagnostic purposes due
to the ability to map the activity of different MMP types at once.

1.4 Objective and scope of dissertation
The objective is to demonstrate MMP detection from CD-free QDs, synthesized
under optimal conditions, characterized, and tested for minimal cytotoxicity. Initially
different Cd-free QDs were synthesized and characterized, which include InP/ZnS,
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InP:Cu/ZnSe, ZnSe:Cu/ZnSe, InP:Mn/ZnSe, ZnSe:Mn/ZnSe, ZnSe:Mn/ZnSeS, and
ZnSe:Mn/ZnS QDs. Eventually, it was determined that ZnSe:Mn/ZnS QDs have the
highest QE (>90%) and stability and became the QDs of choice for the biosensor
development of this dissertation. Following successful development of the synthesis and
characterization of ZnSe:Mn/ZnS QDs, thiol based bioconjugation strategies were
developed for attaching peptides to the QDs. Because it is ultimately intended to use
these Cd-free QD biosensors in vivo, a full cytotoxicity study was conducted on the
ZnSe:Mn/ZnS QD material of interest. Following cytotoxicity studies different strategies
for binding QDs to silica were developed. Finally, the sensitivity of the ZnSe:Mn/ZnS
QD biosensors to MMPs was tested.
Chapter 1 introduces the concepts of MMPs, QDs, biosensors, and the rational for
developing a Cd-free QD-based in vivo MMP biosensor. Chapter 2 details the synthesis
and characterization of ZnSe:Mn/ZnS QDs in chloroform. Chapter 3 details the thiolbased bioconjugation strategy for attaching biomolecules to the ZnSe:Mn/ZnS QDs and
their subsequent dispersion into cerebral spinal fluid (CSF). Chapter 4 contains the details
and the results of the cytotoxicity studies of ZnSe:Mn/ZnS QDs with macrophage cells.
Chapter 5 contains the strategies and results for attaching the ZnSe:Mn/ZnS QDs to
silica. Chapter 6 contains the biosensing data from a commercially available assay and
the developed ZnSe:Mn/ZnS QD biosensors to commercially available active mouse
MMP-9 enzymes. Chapter 7 is the final chapter with concluding remarks and
recommendations.
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Chapter 2
Synthesis and characterization of ZnSe:Mn/ZnS colloidal quantum dots
2.1 Synthesis of highly luminescent Cd-free ZnSe:Mn/ZnS quantum dots
The synthesized ZnSe:Mn/ZnS QDs reached QE above 90%, which was
drastically higher than QE values for any other colloidally synthesized QD materials:
InP/ZnS, InP:Cu/ZnSe, ZnSe:Cu/ZnSe, InP:Mn/ZnSe, ZnSe:Mn/ZnSe, and
ZnSe:Mn/ZnSeS. In addition, the ZnSe:Mn/ZnS QDs did not lose their fluorescence
properties when undergoing any kind of processing. In specific, as a control the
ZnSe:Mn/ZnSeS and ZnSe:Mn/ZnS QDs were subjected to the bioconjugation process
(later described in chapter 3) without the peptide conjugate present (referred to here as
raw processing for clarity) to evaluate how the fluorescence is affected by the steps of the
process itself. Needless to say, ZnSe:Mn/ZnSeS QDs would lose fluorescence as a result
of raw processing and ZnSe:Mn/ZnS QDs would not. Because of their superior
fluorescent properties and resistance to raw processing, ZnSe:Mn/ZnS QDs became the
QDs of choice for the development of the biosensor for this dissertation. In addition, like
the previous doped QDs mentioned, the optical properties of ZnSe:Mn/ZnS QDs possess
thermal stability in comparison to CdSe and ZnSe27, meaning the fluorescence intensity
drops very little in comparison to the fluorescence intensity of CdSe and ZnSe QDs with
increases to temperature.
The colloidal synthesis of ZnSe:Mn/ZnS core/shell QDs is a one pot process; the
synthesis is done all in one reaction vessel without any sub purification steps. The initial
phase of the synthesis involves the formation of ZnSe seeds by reacting zinc stearate and
selenourea. After formation of the ZnSe seeds the Mn precursor is added to the reaction
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at a lower temperature, to allow adsorption of the Mn ions to the surface of the ZnSe
seeds. The temperature is increased in order to diffuse the Mn dopant into the ZnSe
crystal lattice. Multiple injections of Zn precursor solution is added to the reaction vessel
in progressively increasing amounts to add a passivation layer, which results in better
optical properties. Due to the thermal stability of the ZnSe:Mn QDs growing at this point,
the orange fluorescence of the QDs could be monitored with a UV lamp, while the
reaction was still taking place at a temperature of 260 °C. In addition, another passivation
layer was added, a ZnS outer shell, to give the QDs further optical enhancement and
stability.

2.1.1 Basic chemical reactions
1 mmol (95%ZnC36H30O4 + 5%MnC36H30O4) + 1 mmol SeC(NH2)2  1 mmol
Zn0.95Mn0.05Se + 1 mmol C37H34O4N2 (core reaction)
0.90 mmol ZnC36H30O4 + 1.1 mmol SC(NH2)2  0.90 mmol ZnS + 0.20 mmol
SC(NH2)2 + 0.90 mmol C37H34O4N2 (shell reaction)

2.1.2 Synthesis materials
The precursors used to make the core ZnSe:Mn QDs were zinc stearate (ZnSt2),
purchased from Acros Organics, selenourea (SeC(NH2)2), purchased from Aldrich, and
manganese stearate (MnSt2), synthesized in house using anhydrous
manganese(II)chloride (MnCl2), purchased from Acros Organics, and
tetramethylammonium hydroxide pentahydrate (TMAH), purchased from Sigma-Aldrich.
The precursors used to make the ZnS shell of the QDs were zinc stearate (ZnSt2),
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purchased from Acros Organics, and 99% thiourea (SC(NH2)2), purchased from Acros
Organics. The solvents used for the synthesis was octadecene ODE, purchased from
Aldrich, and anhydrous ethanol, purchased from Aldrich. The surfactants used were 80%
- 90% oleylamine, purchased from Acros Organics, and stearic acid (SA), purchased
from Acros Organics.

2.1.3 Synthesis procedure
The Mn-doped ZnSe/ZnS QDs were synthesized under air-free conditions, using a
one-pot method. The synthesis presented forthwith was modified from Pradhan et al
(2007)28 and Acharya et al (2010)29, in that a ZnS shell was added to the nanoparticles
using a thiourea S precursor, and special care was taken to have the synthesis done under
air-free conditions. The ZnS shell modification was sourced from Zhu et al (2010)30.
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(b)

(a)

Figure 2.1: (a) The colloidal synthesis of ZnSe:Mn/ZnS QDs was done in a strictly airfree atmosphere, with precursors prepared under Ar atmosphere and (b) ZnSe:Mn/ZnS
QDs synthesized in octadecene illuminated with a blacklight at high tempterature (235.7
°C), indicating their thermal stability. Precursor solutions were prepared in different
three-neck flasks under Ar by connecting the reaction vessels to a Schlenkline gas
manifold.

Initially, MnSt2 stock powder was synthesized according to supporting
information by Pradhan 2007 et al. First 5.690 g of SA was mixed with 37.89 mL of
methanol in a reaction flask. The reaction flask was purged with Ar, and the solution was
put under stirring and heated to 60 °C until the SA dissolved. Next, the solution was
cooled to room temperature.
3.625 g of TMAH was dissolved into 12.63 mL of methanol and added to the
reaction flask. 1.259 g of the Mn precursor MnCl2 was dissolved into 12.63 mL of
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methanol and added to the primary reaction flask. The resulting mixture was allowed to
react at room temperature and under stirring until a white MnCl2 precipitate formed. The
precipitate was centrifuged in methanol at 4,000 rpm three times and then re-dispersed
into 18 mL of methanol. The solution was dried under vacuum and stored in a 20 mL
vial.
For the QD synthesis, 63 mg of ZnSt2 was dissolved into 5 mL of ODE and
heated to 260 °C in a reaction flask under Ar. In a separate reaction flask, 123 mg of
selenourea (the Se precursor) was mixed with 10 mL of oleylamine 80%-90% and heated
to 200 °C, in order to dissolve the selenourea into the oleylamine, in a separate reaction
flask under Ar. After the selenourea solution cooled to 130 °C, it was injected into the
flask containing the ZnSt2 at 260 °C, after which the temperature was brought to 240 °C.
The Mn dopant was prepared by mixing 6.3 mg of MnSt2 into 3 ml of ODE (additional
heating was required to fully solubilize the Mn precursor). The Mn precursor was
injected into the reaction flask at 240 °C and allowed to react for one hour. For the ZnSe
shell, 1.159 g of ZnSt2 and 0.515 g of SA 97% was mixed with 18.4 mL of ODE. The
ZnSt2 and SA were dissolved into the ODE by heating the mixture under Ar to 150 °C.
The temperature of the reaction was increased to 260 °C (the injection temperature) and
0.96 mL of ZnSt2/SA/ODE was injected and allowed to react for 10 minutes and
subsequently an additional 0.96 mL of the same mixture was added again. The reaction
flask was cooled to 240 °C for 15 minutes and then heated back to the injection
temperature for an injection of 1.33 mL of the of ZnSt2/SA/ODE mixture before setting
the temperature to 240 °C. The injections are repeated in this manner at progressively
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increasing volumes of 1.69 mL, 2.25 mL, and 2.81 mL at the 260 °C injection
temperature, always allowing for a 15 minute anneal step at 240 °C after every injection.
For the ZnS outer shell synthesis, the reaction solution was brought to 70 °C. 86
mg of thiourea was mixed with 3 mL anhydrous ethanol and dissolved with additional
heating. The entire thiourea solution was injected into the reaction flask at 70 °C. In order
to evaporate the ethanol, the solution was put under vacuum and the temperature was
slowly increased, first to 80 °C and then to 120 °C, while always allowing for the
solution bubbling to stop before increasing the temperature. Finally the temperature of
the reaction mixture was increased to 260 °C and 3.65 mL of the ZnSt2/SA/ODE solution
was added. The reaction temperature was then dropped to 240 °C for 30 minutes before
being increased to 260 °C for a final injection of 4.75 mL of the ZnSt2/SA/ODE mixture,
followed by 30 minutes of annealing at 240 °C.
The synthesized QDs were then washed and centrifuged at 4,000 RPM with
acetone for 5 minutes, only once, and finally stored in chloroform.

2.2 Characterization
The ZnSe:Mn/ZnS QDs were structurally characterized with a 2010 JEOL high
resolution transmission electron microscope (HRTEM). In conjunction with HRTEM,
energy-dispersive X-ray spectroscopy (EDS) measurements were made with an X-ray
detector by Oxford Instruments and a high resolution electron energy loss spectrometer.
In addition, X-ray diffraction (XRD) was measured with a Rigaku SmartLab setup using
a Cu source operating at 40 kV – 44 mA, with a 0.02° step size and a 4°/min scan rate.
The scanning range was 10 – 80° 2θ.
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Optical characterization was carried out with a Joriba Joban Yvon Fluorolog – 3
spectrofluorometer for photoluminescence measurements, a Cary 5000 UV-Vis-NIR dual
beam spectrometer, and dynamic light scattering (DLS) measurements were made with
Wyatt Dynapro DLS system. Quantum efficiency measurements were made with a 4 inch
integrating sphere.

2.2.1. Transmission electron microscopy
In preparation for TEM imaging, the ZnSe:Mn/ZnS QDs in chloroform were
dropped and dried onto a copper grid. In order to induce super-lattice self-assembly,
when dropping the QD solution, a solvent immiscible with chloroform, two drops of
water in this case, was first dropped onto the grid, following two drops of the QD
solution. Utilizing this coordinating solvent method, the QDs self-assemble into a highly
ordered lattice, upon drying31.
The imaged ZnSe:Mn/ZnS QDs from the 2010 JEOL high resolution transmission
electron microscope (HRTEM) can be observed in Figure 2.2a-f. Ten images were used
in conjunction with Digital Micrograph Software to analyze the size of these particular
QDs; the average overall diameter turned out to be 5.48 nm, assuming spherical shape.
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(a)

(b)

(d)

(c)

(e)

(f)

Figure 2.2: (a)-(f) transmission electron microscopy images of ZnSe:Mn/ZnS QDs. The
scale bars are 20 nm.
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2.2.2 Energy-dispersive X-ray spectroscopy
Figure 2.3 is an energy x-ray dispersive spectroscopy EDS spectrum for
ZnSe:Mn/ZnS QDs dried onto a TEM grid. Note the presence of all four required
elements Zn, Se, S, and Mn. The Cu and C signals are a result of the TEM grid.

Figure 2.3: EDS spectrum for ZnSe:Mn/ZnS QDs confirming the presence of Zn, Se, Mn,
and S.

2.2.3 X-ray diffraction
In order to identify the actual phases of the nanomaterial that results from the
ZnSe:Mn/ZnS QD synthesis, XRD measurements were taken with a a Rigaku SmartLab
XRD setup, using a Cu source operating at 40 kV – 44 mA, with a 0.02° step size and a
4°/min scan rate. In preparation for the XRD measurement, colloidal ZnSe:Mn/ZnS QDs
were dropped onto a zero background holder. Figure 2.4 is the XRD pattern the sample
produced. From the XRD pattern three phases were identified from the International
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Centre for Diffraction Data (ICDD): zinc selenide (ZnSe), zinc selenium sulfide
(ZnSe0.74S0.26), and zinc manganese selenide (Zn0.95Mn0.05Se).

Figure 2.4: Powder XRD spectrum for ZnSe:Mn/ZnS QDs.

2.2.4 Dynamic light scattering
In order to obtain the average-size and size-distribution, based on the
hydrodynamic radius, a measurement using DLS was taken. The ZnSe:Mn/ZnS QDs
were diluted in chloroform before the measurement. Figure 2.5 is the resulting size
histogram obtained from DLS, indicating an average hydrodynamic radius of 10.72 nm
with a size distribution ranging between ~

1 to 35 nm. The average radius obtained

from DLS suggests the particle size to be significantly larger than the 5.48 diameter
particle size determined by processing the TEM images through the Digital Micrograph
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software. This is likely due to the fact that there is an additional organic layer coating the
QDs, the stearic acid surfactant, which cannot be imaged with TEM, and therefore only
the inorganic component of the QDs show on TEM. Size data as obtained from DLS
accounts for both the inorganic (ZnSe:Mn/ZnS) and organic (stearic acid) surfactant
components of the QDs. Stearic acid is a long molecule with an 18 carbon chain, which
likely accounts for the size difference.
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Figure 2.5: DLS spectrum for ZnSe:Mn/ZnS colloidal QDs in chloroform indicating a
reasonably good size distribution with an average hydrodynamic radius of 10.72 nm.
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2.2.5 Zeta Potential
The zeta potential for ZnSe:Mn/ZnS colloidal QDs in chloroform was measured
with a Malvern Zetasizer. The zeta potential distribution can be viewed in Figure 2.6.
The zeta potential is 54.6 mV, which, being between 40 to 60 meV, is indicative of good
colloidal stability.

Figure 2.6: Zeta potential distribution for ZnSe:Mn/ZnS QDs in chloroform showing a
peak value of 54.6 mV in the zeta potential distribution curve.

2.2.6 Absorption
Absorption for ZnSe:Mn/ZnS QDs in chloroform was by measured with a Varian
Cary 5000 UV-Vis-NIR spectrophotometer by scanning absorption over 250 nm – 600
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nm range, measuring ZnSe:Mn/ZnS QDs in chloroform and pure chloroform. With the
dual beam functionality of the spectrophotometer, absorption of pure chloroform was
subtracted from the absorption of the colloidal nanocrystal sample, giving an absorption
spectrum of the nanocrystals alone (Figure 2.7).
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Figure 2.7: Absorption spectrum for ZnSe:Mn/ZnS QDs in chloroform indicating a small
feature around 416 nm wavelength.

2.2.7 Photoluminescence and quantum efficiency
The photoluminescence excitation (PLE) and photoluminescence (PL) for
colloidal Zn0.95Mn0.05Se/ZnS QDs in chloroform can be observed from the spectra in
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Figure 2.8 (a) and (b), respectively. The sample has a bright orange (597 nm) emission
wavelength when excited with near UV (320- 400 nm) wavelength, which is believed to
be an atomic energy transition from the manganese dopant. The optimal wavelength as
indicated by the PLE spectrum indicates 380 nm optimal excitation wavelength.
However, 400 nm wavelength was used to determine the high 86.5% QE, due to the fact
that the integrating sphere absorbs UV wavelength. Additionally, as can be seen from
Figure 2.9 (a) and (b), there is another PL emission feature that can be observed at 487
nm emission wavelength (QE 4.2%) by exciting with a longer 436 nm wavelength. Based
on past findings, when making these Zn0.95Mn0.05Se/ZnS QDs hydrophilic with
mercaptoacetic acid, via thiol binding to the surface, this 487 nm emission disappears,
only leaving the orange 597 nm emission.
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Figure 2.8: PL (a) excitation and (b) emission spectra for Zn0.95Mn0.05Se/ZnS
colloidal QDs in chloroform. For the excitation spectrum (a) 596 nm parked emission
wavelength was used to generate the spectrum. For the emission spectrum (b) 400 nm
excitation wavelength was used to generate the spectrum. The emission observed in
(b) is due to the Mn atomic energy level transitions as a result of the Mn doping in the
nanocrystals. The QE for this particular emission peak is 86.5%.
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Figure 2.9: Surface defect PL (a) excitation and (b) emission spectra for
Zn0.95Mn0.05Se/ZnS colloidal QDs in chloroform. For the excitation spectrum (a) 487 nm
parked emission wavelength was used to generate the spectrum. For the emission
spectrum (b) 436 nm excitation wavelength was used to generate the spectrum. The
emission observed in (b) at 595 nm wavelength is due to the Mn atomic energy level
transitions as a result of the Mn doping in the nanocrystals and the emission observed at
487 nm is believe to be surface defect related and is highly sensitive to surface
modification. The QE for the surface defect emission peak is 4.2%.

2.3 Summary
All in all, the synthesis of highly luminescent, stable ZnSe:Mn/ZnS QDs was
successful and has been duplicated several times. The 597 nm Mn emission is relatively
stable in comparison to that of the 487 nm surface defect emission, which lowers in QE at
a faster rate than the Mn emission. The specific time evolution of the QE stability can be
observed in Figure 2.10. Note the greater rate at which the QE lowers for the surface
defect emission Figure 2.10b.
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Figure 2.10: (a) and (b) time evolved QE for Mn and surface defect emission,
respectively for ZnSe:Mn/ZnS QDs.

As a result of the dropping QE, during the next phases of this research
(bioconjugation, cytotoxicity, silica linking, and biosensing) the QDs were freshly
synthesized about once every two months.
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Chapter 3
MMP substrate peptide conjugation to ZnSe:Mn/ZnS quantum dots

3.1 QD peptide conjugation
There are a number of bioconjugation strategies for linking biomolecules to QDs,
such as EDC linker molecules, streptavidin / biotin affinity, click chemistry, and thiolmetal affinity. Since the intended QD biosensor would rely on modifications to the
biomolecule on the surface of the QD, it would be best to minimize the space between the
sensing biomolecule and the luminescent QD surface. Therefore it is intended to use the
thiol / metal affinity strategy to link the polypeptides with the small molecule, cysteine.
Cysteine contains a thiol molecule, which will bond to metals32.

3.2 Bioconjugation concept (biosensor assembly)
A polypeptide/QD bioconjugation process was modified from the work of Shi et
al 2007. A basic solution containing a mix of benzylamine and dimethylformamide with
the Zn0.95Mn0.05Se/ZnS core/shell QDs and MMP-9 peptide substrate molecules were
mixed vigorously with a fixed vortexer. After which, they were washed with PBS and
purified with spin dialysis using Microcon 30 kDa centrifuge filters. Figure 1 illustrates
the simplicity of the idea, where a 9-amino-acid residue polypeptide containing the
MMP-9 substrate peptide motif as well as a cysteine amino-acid residue at the Cterminus, due to the thiol-metal affinity, covalently bonds to the zinc sulfide surface of
the QDs, directly between sulfur and the metallic surface.
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Zn0.95Mn0.05Se/ZnS
core/shell quantum dot

MMP-9
polypeptide
substrate

MMP-9 biosensing
quantum dot conjugate

Figure 3.1: Illustration depicting the bioconjugation process, the assembly of the QDbased biosensor. Due to the thiol-metal affinity, the thiol group in the cysteine amino acid
residue on the C-terminus of the polypeptide forms a covalent bond, via nucleophilic
substitution reaction, to the surface of the QD.

3.3 Bioconjugation process
Certain modifications were made from the procedure developed by Shi et al 2007,
which include replacing pyridine with benzylamine, because pyridine was etching the
QDs, causing these particular Zn0.95Mn0.05Se/ZnS QDs to lose a significant portion of
their fluorescence intensity. Also, because the benzylamine is already basic, with a
measured pH of 11.34, no tetramethyl ammonium hydroxide was added to increase the
pH. The reason pH is increased is to negatively charge the thiol groups in order to
facilitate the binding of the peptides with the QDs.
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3.3.1 Materials
For biofunctionalization, the cys-containing peptides were purchased from
GenScript; 99% benzylamine was purchased from Acros Organics; dimethylformamide
was purchased from EMD; pH 7.4 phosphate buffered saline solution (PBS) was
purchased from Gibco, and artificial cerebral spinal fluid was purchased from Harvard
Apparatus.

3.3.2 Procedure
This procedure is a modification of a protocol by [Shi 2007].
1 mL of Zn0.95Mn0.05Se/ZnS QDs in chloroform (as synthesized) was centrifuged
with acetone at 4,000 RPM. After pouring off the supernatant, the QDs were resuspended in 2 ml of 9:1 (v:v) benzylamine/dimethylformamide (DMF) solution. 1 mg of
the MMP-9 peptide substrate was dissolved into 0.200 mL of DMF. The peptide/DMF
solution was added to the QD/benzylamine/DMF solution, and the resulting mixture was
vortexed for 30 minutes. The peptide/QD conjugates were centrifuged and redistributed
in 2 mL of DMF. The mixture was centrifuged again and re-dispersed in 2 mL of PBS.
The peptide/QD conjugate solution was subjected to 2 cycles of spin dialysis by using 4
Microcon (ultracell YM-30) centrifugal filter devices. Afterwards, the peptide/QD
conjugates were dispersed into 2 mL of PBS and stored in a fridge at 4 °C.
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3.4 Characterization
Two different batches consisting of the Zn0.95Mn0.05Se/ZnS QDs/peptide
conjugates containing the substrate and remnant peptides were measured with a Wyatt
dynamic light scattering apparatus. In order to verify the difference in hydrodynamic
radius as a result of the different lengths between the remnant and substrate peptides, a
size distribution was measured for both samples.

3.4.1 Dynamic light scattering (DLS)
In figure 3.2 (a) and (b) a small decrease in the average hydrodynamic radius can
be observed from 3.53 to 3.26 nm.
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Figure 3.2: Size distribution histograms as generated by dynamic light
scattering (DLS) for Zn0.95Mn0.05Se/ZnS core/shell quantum dots
conjugated with (a) polypeptides containing 9 amino acid residues and
(b) polypeptides containing 4 amino acid residues. Though there’s not
much of a change, the average hydrodynamic radius does decrease for
the remnant peptides.
37

9

10

(b)

3.4.2 Zeta potential
Additionally, in order to see if some sort of correlation with surface charge could
be made with the increasing QE as a result of the increasing remnant peptide percentage,
a series of zeta potential measurements were made with a Malvern Zetasizer (Figure
3.3). Solutions were mixed to contain 0%, 25%, 50%, 75%, and 100% remnant
peptide/substrate peptide ratios. The Zeta potential increased, overall, from substrate to
remnant peptide/QD conjugates, suggesting that the percentage of remnant polypeptide
MMP-9 substrates does in fact have an effect on the surface charge of these particular
QDs.
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Figure 3.3: Plot indicating how zeta potential changes with increasing
percentage of cleaved peptides.
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3.4.3 Absorption
Absorption was measured using a Varian Cary 5000 UV-Vis-NIR
spectrophotometer for substrate and remnant peptide/ Zn0.95Mn0.05Se/ZnS QDs in PBS by
scanning between 200 – 800 nm, which can be observed in Figure 3.4. Both absorption
lines possess a feature at 257 nm, with the substrate peptide/QD feature being slightly
lower in absorption than the remnant peptide/QD feature.

1.0
0.9

257 nm
Substrate peptide/QD conjugates
Remnant peptide/QD conjugates

Absorption

0.8
0.7
0.6
0.5
0.4
0.3
240

260

280

300

320

340

360

380

400

420

440

Wavelength [nm]

Figure 3.4: Absorption spectra for substrate and remnant Zn0.95Mn0.05Se/ZnS QDs in
PBS. Both lines exhibit a feature at 257 nm.
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3.4.4 Photoluminescence and quantum efficiency
A Horiba Joban Yvon spectrofluorometer was used to characterize the
photoluminescence (PL) and photoluminescence excitation (PLE) properties, and the
quantum efficiency (QE) of Zn0.95Mn0.05Se/ZnS QDs in chloroform and
Zn0.95Mn0.05Se/ZnS/peptide QD conjugates.
As described in chapter 2, Zn0.95Mn0.05Se/ZnS QDs has a bright orange (597 nm)
emission wavelength when excited with near UV (320- 400 nm) wavelength, which is
believed to be an atomic energy transition from the manganese dopant. Additionally,
there is another PL emission feature that can be observed at 487 nm emission wavelength
(QE 4.2%) by exciting with a longer 436 nm wavelength, which is believed to be surface
defect related.
Based on past findings, when making Zn0.95Mn0.05Se/ZnS QDs hydrophilic with
mercaptoacetic acid, via thiol binding to the surface, this, surface defect related, 487 nm
emission disappears, only leaving the orange 597 nm emission. The past hydrophilization
experiments were successful because the previously hydrophobic stearic acid capped
Zn0.95Mn0.05Se/ZnS QDs became readily dispersible in water due to the thiol bonding of
mercaptoacetic acid to the metallic ZnS surface. Because of this, observing the loss of the
487 nm surface defect emission can be used as a verification to ensure that the peptides
have bonded to the QD surfaces via thiol boding from the cysteine residue.
When applying the peptide conjugation procedure, the 487 nm surface defect
emission does in fact go away. Most remarkably is that the QE of the orange 593 nm
emission drops to 39.1%.
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Figure 3.5 (a) and (b) are the PLE and PL spectra for colloidal
Zn0.95Mn0.05Se/ZnS/peptide conjugates in PBS, respectively. The optimal excitation red
shifts considerably to 318 nm, as opposed to 380 nm for the non-conjugated QDs studied
in Figure 6. When the remnant peptides (the 4 amino acid peptide that results after MMP9 cleaves it) were conjugated to the colloidal Zn0.95Mn0.05Se/ZnS QDs, the QE ends up
being 90.8%. Figure 3.6 (a) and (b) are the PLE and PL spectra, respectively, for the
peptide/QD conjugated using the remnant peptide.
Again 400 nm excitation wavelength was used to excite the samples in the
integrating sphere during QE measurement because the walls of the integrating sphere
absorb UV. This drastic change between QE, 39.1% to 90.8%, for the substrate and
remnant samples is a notable preliminary result for the viability of these particular
peptide/QD conjugates as a biosensing system of MMP-9 enzymes.
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Figure 3.5: (a) excitation and (b) emission spectra for Zn0.95Mn0.05Se/ZnS/peptide
colloidal QD conjugates in PBS with the substrate 9 amino acid residue
polypeptide. For the excitation spectrum (a) 596 nm parked emission wavelength
was used to generate the spectrum. For the emission spectrum (b) 320 nm excitation
wavelength was used to generate the spectrum, which has a 595 nm maximum
emission wavelength. The emission observed in (b) is due to the Mn atomic energy
level transitions as a result of the Mn doping in the nanocrystals. The QE for this
particular emission peak is 39.1%, as determined from the integrating sphere with
an excitation of 400 nm.
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Figure 3.6: (a) excitation and (b) emission spectra for Zn0.95Mn0.05Se/ZnS/peptide
colloidal QD conjugates in PBS with the substrate 4 amino acid residue
polypeptide. For the excitation spectrum (a) 597 nm parked emission wavelength
was used to generate the spectrum. For the emission spectrum (b) 315 nm
excitation wavelength was used to generate the spectrum. The emission observed in
(b) is due to the Mn atomic energy level transitions as a result of the Mn doping in
the nanocrystals. The QE for this particular emission peak is 90.8%, a dramatic
increase from the substrate sample seen in Figure 3.3.
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The reliability of this biosensing idea was further tested by ensuring that the QD /
peptide ratio was the same during peptide bioconjugation for both the substrate and
remnant polypeptides, by diluting the QDs undergoing conjugation with the substrate
peptide to 1 µM and the QDs undergoing conjugation with the remnant peptide to 2 µM
in chloroform. This is because 1 mg of remnant peptides is nearly twice as many moles as
1 mg of the substrate peptides.

3.5 Dilution factor determination
The protocol by Shi et al 2007 called for a 1 µM concentration of QD sample as a
starting point. As the Zn0.95Mn0.05Se/ZnS QDs were heavily concentrated after synthesis a
protocol for measuring the particle molarity was developed. In addition concentration
was be determined by just how much chloroform solvent dilution was required to reach 1
µM concentration for substrate peptide and 2 µM for remnant peptide. The MW for the
substrate peptide ({val}{val}{pro}{leu}{ser}{leu}{arg}{ser}{cys}) is 973.20, and the
MW for the remnant peptide ({leu}{arg}{ser}{cys}) is 477.58. 1 mg of substrate peptide
is equivalent to 0.001 mmol, and 1 mg of remnant peptide is equivalent to 0.002 mmol.
To determine how much chloroform is needed to dilute the colloidal QD solution
a number of measurements and calculations were made.
First 1 mL of the sample was dried and then calcinated at 750 °C, in an oven, in
order to determine a QD mass per solution volume concentration.
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In order to determine the particle molarity, the reactions of the synthesis has to be
analyzed, first. (Rxn. 1) is the chemical reaction for the synthesis of the core
(Zn0.95Mn0.05Se) phase of the QDs.
1 mmol (95%ZnC36H30O4 + 5%MnC36H30O4) + 1 mmol SeC(NH2)2  1 mmol
Zn0.95Mn0.05Se + 1 mmol C37H34O4N2

(Rxn. 1)

1 mmol Zn0.95Mn0.05Se Phase. 1
(Rxn. 2) is the chemical reaction for the synthesis of the shell (ZnS) phase of the QDs.
0.90 ZnC36H30O4 + 1.1 SC(NH2)2  0.90 mmol ZnS + 0.20 mmol SC(NH2)2 + 0.90
mmol C37H34O4N2 (Rxn. 2)
0.90 mmol ZnS Phase. 2
Knowing both of the reactions for phase 1 and phase 2, the core and the shell,
respectively, of the Zn0.95Mn0.05Se/ZnS QDs the theoretical molar quantities can be
determined, which are 1 mmol for Zn0.99Mn0.01Se (phase 1) and 0.90 mmol for ZnS
(phase 2), after which, Eqn. 3 and 4 can be used to determine the mass quantity of phase
1 and phase 2. By knowing the mass quantities for
masses,

and

and

, the percent

can be calculated from Eqn. 1 and 2.
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Where

and

are the molecular weight of Zn0.95Mn0.05Se and ZnS,

respectively.
Eqn. 5 is the total sample mass, which was determined, as stated before, through drying
and calcination of 1 mL of as synthesized Zn0.95Mn0.05Se/ZnS QD sample in chloroform.

The sample masses for the two separate phases are determined from Eqn. 6 and 7.

Using the densities and molecular weights of the two different phases, the separate
volumes for each sample can be calculated from Eqn.8 and 9.
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Where

,

,

, and

are the molarities and densities of

Zn0.95Mn0.05Se and ZnS, respectively.

The total volume of the sample can be determined from Eqn. 10, and the volume of a
single Zn0.95Mn0.05Se/ZnS QD from Eqn. 11. Take the total volume of the sample and
divide it by the volume of a single Zn0.95Mn0.05Se/ZnS QD to determine the total number
of QDs in the sample, as in Eqn. 12. The QDs were estimated as circles with an average
radius of 2.74 nm, as determined by TEM.

Calculate the particle molarity from Eqn. 13. In order to determine how much chloroform
solvent to dilute the sample with in order to achieve a 1 µM concentration, a spreadsheet
was used to develop a plot of Particle Molarity vs. Dilution (Figure 3.7).
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Figure 3.7: A plot for determining how much chloroform solvent to use to dilute 3.2
mg/mL of Zn0.95Mn0.05Se/ZnS QDs in chloroform.

For substrate peptide bioconjugation, 1 mL of 1 µM Zn0.95Mn0.05Se/ZnS QDs in
chloroform was centrifuged with acetone at 4,000 RPM. After pouring off the supernatant
the QDs were re-suspended in 2 ml of 9:1 (v:v) benzylamine/dimethylformamide (DMF)
solution. 1 mg of the MMP-9 peptide substrate was dissolved into 0.200 mL of DMF.
The peptide/DMF solution was added to the QD/benzylamine/DMF solution, and the
resulting mixture was vortexed for 30 minutes. The peptide/QD conjugates were
centrifuged and redistributed in 2 mL of DMF. The mixture was centrifuged again and redispersed in 2 mL of PBS. The peptide/QD conjugate solution was subjected to 2 cycles
of spin dialysis by using 4 Microcon (Ultracell YM-30) centrifugal filter devices.
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Afterwards, the peptide/QD conjugates were dispersed into 2 mL of PBS, resulting in 0.5
µM particle concentration, and stored in a fridge at 4 °C.
Similarly, for remnant peptide bioconjugation, the same procedure was followed,
with the added exception that 1 ml of 2 µM Zn0.95Mn0.05Se/ZnS QDs in chloroform was
centrifuged with acetone at 4,000 RPM, at the start, and the final peptide/QD conjugates
were dispersed into 4 mL of PBS, giving a final concentration of 0.5 µM particle
concentration.
With the QD / peptide ratios the same for both batches and the samples
normalized to 0.5 µM after bioconjugation, the QE values still increased between
substrate and remnant peptide from 1.7% to 20%. Figure 3.8 is the PL intensity
dependence on the percentage of remnant peptides from 0%, 25%, 50%, 75%, and 100%
for Zn0.95Mn0.05Se/ZnS/peptide conjugates, all normalized to 0.5 µM. Furthermore,
Figure 3.9 illustrates the QE dependence on the percentage of remnant peptides from
0%, 25%, 50%, 75%, and 100% for Zn0.95Mn0.05Se/ZnS/peptide conjugates, all
normalized to 0.5 µM, as well. This substantial increase in PL intensity and QE% is an
indication of a fluorometric method for quantifying MMP-9 enzyme activity levels, in
which fluorescence increases with MMP activity.
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Figure 3.8: A PL emission intensity vs. percent peptide cleavage plot
indicating that with normalized concentrations intensity still increases as a
function of cleaved peptide percentage.
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with normalized concentrations QE also increases as a function of cleaved
peptide percentage.
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3.6 Photoluminescence of peptide conjugated QDs in CSF
As the overall idea with this biosensor development is in vivo biosensing in
cerebral spinal fluid (CSF), the Zn0.95Mn0.05Se/ZnS/peptides QD bioconjugates were
dispersed in sterile CSF, and the PLE and PL of the remnant and substrate peptides were
characterized, and, fortunately, the optical behavior was similar to the QD bioconjugates
in PBS, in that the remnant peptide QD bioconjugates were far less quenched than the
substrate. The QE increases from 2.6 % to 9.2% between substrate and remnant peptide,
respectively. Note the 5 nm blue shift from the emission between substrate and remnant
peptide bioconjugates in Figure 3.10 and Figure 3.11.

(a) 1200000

30000

600000

25000

Intensity [CPS]

800000

a.u.

600nm

JPMF_090613
1_ZnSe_Mn_peptide_MMP9_4_CSF
PL_MF090913
FFDetection
Em. 1
Ex. 1
emission 600

1000000

400000

200000

20000

15000

JPMF_090613
1_ZnSe_Mn_peptide_MMP9_4_CSF
PL_MF090913
FFDetection
Em. 1
QE: 2.1%
Ex. 1
excitation 314

(b)

10000

5000

0

0

300

350

400

450

500

550

600

300

Wavelength [nm]

350

400

450

500

550

600

650

Wavelength [nm]

Figure 3.10: PLE (a) and PL (b) spectra for substrate peptide coated ZnSe:Mn/ZnS
core/shell QDs in CSF using 600 nm parked emission for PLE and 314 nm parked
excitation wavelength for PL. The QE is 2.1%.
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Figure 3.11: PLE (a) and PL (b) spectra for remant peptide coated ZnSe:Mn/ZnS
core/shell QDs in CSF using 593 nm parked emission for PLE and 312 nm parked
excitation wavelength for PL. The QE is 9.2 %.

3.7 Summary
Encouragingly, the 9 amino-acid peptide substrate does have a quenching effect
on the fluorescence of the Zn0.95Mn0.05Se/ZnS colloidal QDs when it is bioconjugated at
the surface of the ZnS shell. Even more exciting is that the fluorescence is quenched
much less when conjugating the 4 amino-acid peptide (what the longer peptide will look
like after it is cleaved by MMP-9). Whether this will result in a de-quenching effect when
these particular peptide/QD (substrate) conjugates are incubated with active MMP-9
remains to be seen, but if there ends up being a significant brightening of the quenched
fluorescence, then it is the first step to realizing the proposed in vivo, quantitative,
multiplexing, real time biosensing system for matrix metalloproteinase.
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Chapter 4
ZnSe:Mn/ZnS QD-based MMP-9 biosensing experiments
4.1 ZnSe:Mn/ZnS QDs and peptide property dependent effects on QD
fluorescence
Clinically relevant concentrations of MMPs depend on the MMP type. For
instance, diabetic patients express MMP-2 at levels around 1000 – 1500 ng/mL, MMP-8
at around 5 ng/mL, and MMP-9 at 400 – 800 ng/mL for MMP-9 in serum33, as was
determined using enzyme-linked immunosorbent assay (ELISA). These levels are only
slightly elevated from that of the healthy controls. As for the CSF, active MMP-9s are
generally expressed at 1.80 ± 0.63 ng/mL for healthy individuals and 7 ± 2.4 ng/mL for
seizure patients34. In comparison to MMP-9 levels in serum, in would seem that active
MMP-9 is expressed at far lower concentrations in CSF. In addition, MMP activity can
be detected as early as in 20 minutes, via the use of bioluminescent quencher/QD
conjugates35.
In the case of fluorescent peptide/QD conjugates, as was discussed in Chapter 3,
the length of the peptide appeared to affect the QY. Specifically, cys-containing
peptide/QD conjugates containing 9 amino-acid (AA) residues have lower QY than cyscontaining peptide/QD conjugates containing 4 AA residues. This phenomenon was the
first step in lending credence to the idea of ZnSe:Mn/ZnS peptide/QD conjugates as
nano-biosensors for MMP activity, quantifying MMP activity based on the change in
fluorescence as a result of MMPs cleaving peptides.
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However, upon further consideration, it appears that peptide length may not be the
sole reason for the change in fluorescence observed between the remnant and substrate
peptide/QD conjugates. Additional peptide properties, such as charge and
hydrophobicity, most likely account for the change in fluorescence as well.
Using the Peptide Property Calculator from Genscript36, the vendor which
supplied the peptides used in these experiments, several properties of three different
peptides were calculated: molecular weight (MW), charge, isoelectric point, acidity, and
hydrophobicity.
The three peptides examined were the 9 AA substrate cys-containing peptide,
{Val}{Val}{Pro}{Leu}{Ser}{Leu}{Arg}{Ser}{Cys}; the 4 AA cys-containing remnant
peptide, {Leu}{Arg}{Ser}{Cys}; and the14 AA cys-containing peptide,
{Glu}{Asp}{Glu}{Asp}{Glu}{Val}{Val}{Pro}{Leu}{Ser}{Leu}{Arg}{Ser}{Cys}. The
14 AA peptide possesses the same MMP-9 substrate motif as in the 9 AA peptide;
however, additional negatively charged aspartic acid {Asp} and glutamic acid {Glu}
residues were added to the AA sequence to give the peptide an overall charge of -4,
making it acidic, as well as decreasing the molecule’s hydrophobicity from that of the
substrate 9 AA peptide, making it more stable in aqueous media. The 9 AA peptide has a
charge of +1, is basic, and has a higher hydrophobicity than the 14 AA peptide.
In observing the PL behavior between the 14 AA peptide/QD conjugates and the
4 AA peptide/QD conjugates, the QY of the 14 AA is higher than the 4 AA peptide/QD
conjugates, which is opposite to the case of the 9 AA and the 4 AA peptide/QD
conjugates, as described in Chapter 3. This means that it is not necessarily the length of
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the peptide of the conjugates but rather other properties, such as peptide charge and
hydrophobicity, which may be responsible for the change in QY, as the charge between
the 14 AA peptide (-4) is quite different from the charge of the 9 AA and 4 AA peptide
(+1). The hydrophobicity for the three different peptides is different as well.
In this chapter, various biosensing data are presented on the sensitivity of the
peptide-coated ZnSe:Mn/ZnS QDs, discussed throughout the dissertation up to this point,
to active MMP-9 enzymes. The sensitivity of the peptide/QD conjugates to MMP-9
enzymes is analyzed based on MMP and QD concentration, sensing media; water or CSF
medium, as well as the substrate peptide type, 14 AA and 9 AA peptides.

4.2 Commercial assay from Anaspec
The active MMP-9 enzymes used in this research were purchased from Anaspec.
To verify the MMP activity, a commercial assay, SensoLyte® 520 MMP - 9 Assay Kit,
also from Anaspec, was used. This is a fluorometric assay that utilizes FRET pairing
between quenchers (QXL520TM) and fluorophores (5-FAM), linked by an MMP peptide
substrate; the AA sequence of the substrate, here, is proprietary. Upon cleavage by the
active MMPs, the FRET pairs are separated and the previously quenched fluorescence is
restored. The technique allows for continuous and endpoint measurements at 490 nm
excitation and 520 nm emission wavelengths.
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4.2.1 Materials
Mouse MMP - 9 (Recombinant, Catalytic Domain) and the SensoLyte® 520 MMP
- 9 Assay Kit were purchased from Anaspec. 384 well plates were purchased from
Thermo Scientific, and artificial CSF was purchased from Harvard Apparatus.

4.2.2 Assay procedure
The procedure was based on the protocol supplied by Anaspec37. MMP-9
enzymes were diluted in assay buffer to concentrations of 2 µg/mL, 0.2 µg/mL, 0.02
µg/mL, and 0.002 µg/mL. The MMP-9 substrate was diluted in assay buffer to a ratio of
1:100. The different MMP-9 dilutions were added to triplicate wells, 20 µL per well.
Additionally, triplicate wells were setup to have 20 µL of 2 µg/mL, 0.2 µg/mL, 0.02
µg/mL, 0.002 µg/mL, and 0 µg/mL solution. 20 µL of the assay MMP substrate was
added to all wells, creating overall concentrations of 1 µg/mL, 0.1 µg/mL, 0.01 µg/mL,
0.001 µg/mL, and 0 µg/mL MMP9 solutions. The reagents were mixed by gently shaking
the orbital plate for 30 seconds.

4.2.3 Assay results
In a Tecan Infinite 200 PRO Microplate Reader, the fluorescence was monitored
at 490 nm excitation and 520 nm emission wavelength at 5 minute intervals, using 100%
gain. The assay manual instructs that the measurements be taken over the course of 30 to
60 minutes. However, the measurements were done beyond 60 minutes. Still, the
measurements could be repeated and continued for an even longer time because the
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signal for 1000 ng/mL MMp-9 is still increasing and measurements should continue until
the signal saturates. During the first run of measurements, the MMP-9 kinetics was
studied at room temperature. The data are shown in Figure 4.1. Very little sensitivity can
be observed between 0 to 100 ng/mL concentrations. Measurements with 1,000 ng/mL
MMP-9 wells show a clear signal, as indicated by the higher slope on the kinetics line in
Figure 4.1.
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Figure 4.1: MMP-9 activity kinetics at room temperature as measured with the
SensoLyte® 520 MMP - 9 Assay Kit.
The second set of measurements, again using 490 nm excitation and 520 nm
emission wavelength at 5 minute intervals, was done with the internal temperature of the
microplate reader set to 37 °C. As shown in Figure 4.2, the first 35 minutes, the signals
from the 0 to 100 ng/mL samples again show little sensitivity, with the 1,000 ng/mL
sample giving the highest signal. Since the results were practically the same as those
obtained at room temperature, it was concluded that the internal heater in the microplate
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reader was faulty. After 35 minutes, the well plate was transferred to a CO2 incubator at
37 °C. The proceeding measurements indicated a significant increase in MMP-9 activity,
which can be noticed in the Figure 4.2 plot. After undergoing a half hour of incubation,
as is also illustrated in Figure 4.2, the sensitivity for MMP-9 at the 100 ng/mL
concentration goes up significantly, becoming more discernable on the spectra, unlike the
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previous measurements without incubation.
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Figure 4.2: MMP-9 activity kinetics at 37°C as measured with the SensoLyte® 520 MMP
- 9 Assay Kit. The microplate reader was set to 37°C for the first 35 minutes, but the rate
increase is a result of the samples being in a CO2 incubator at 37°C for 30 minutes,
suggesting that the internal heater in the plate reader was faulty.
The 0 ng/mL MMP-9 activity curves in both Figures 4.1 and 4.2 shows a signal
that slightly increases with time. Ideally it should be flat, but, as was confirmed with the
vendor, there is sometimes a small increase in background. This background did not turn
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out to be temperature dependent. Temperature does in fact affect enzyme activity,
however, observation of Figures 4.1 and 4.2 does not show any clear indication of
temperature dependency with regards to MMP-9 activity. Testing for MMP-9 activity at
41.5 ºC, in what is considered to be extreme body temperature elevation, does not show
any noticeable increase in MMP-9 activity (Figure 4.3).
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Figure 4.3: Fluorometric response of MMP assay substrate for 1000 ng/mL MMP9 with
increasing temperature from 27.5 ºC to 41.5 ºC.

4.3 Verifying QD emission in the plate reader
Before testing the sensitivity of the peptide/QD conjugates to MMP-9 enzymes, it
was at first important to verify the ability to detect QD fluorescent emission using the
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particular Tecan Infinite 200 PRO microplate reader microplate reader, with the optimal
excitation (319 nm) and emission (595 nm) wavelengths.

4.3.1 Procedure
In a 384-well plate, five wells were loaded with 20 µL volumes of the peptide/QD
conjugates (synthesized according to the protocol outlined in Chapter 3) in CSF, with
concentrations of 0.25 µM, 0.13 µM, 0.06 µM, 0.03 µM, and 0 µM.

4.3.2 Results
At first, using 319 nm excitation and 595 nm emission wavelengths, no reading
could be observed from the fluorescent conjugates, using 100 % gain. The gain was
tested at 10 % intervals from 100 to 10 %, and no signal could be observed. However,
upon setting the gain to ‘optimal’, in which the machine optimizes the gain in order to
receive the best measurement, the fluorescent readings could finally be observed. The
optimal gain setting was 255%, which is the maximum gain. Figure 4.4 shows the
fluorescent signals from the peptide/QD conjugates for varying QD concentration. As
expected, the fluorescence intensity decreases with the QD concentration.
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Figure 4.4: QD fluorescence with respect to concentration as read from the Tecan
microplate reader, set on ‘optimal’ gain.

4.4 MMP-9 biosensing (positively charged peptide)
Following successful detection of QD emission from the microplate reader, the
experiment protocol for MMP-9 QD-based biosensing was developed. Taking the results
of cytotoxicity studies (outlined in Chapter 6) into consideration, the first biosensing
experiment was set up to have the peptide/QD conjugates at a constant concentration of
0.13 µM, a concentration which showed minimal cytotoxic effect on macrophage cells,
with varying MMP-9 solutions of 1000 ng/mL, 100 ng/mL, 10 ng/mL, 1 ng/mL, and 0
ng/mL, the same that was used in the commercial assay. Furthermore, the experiment was
done in two different media, water and CSF.
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4.4.1 Materials
Active mouse MMP - 9 (Recombinant, Catalytic Domain) enzymes were
purchased from Anaspec. 384 well plates were purchased from Thermo Scientific and
artificial CSF was purchased from Harvard Apparatus.

4.4.2 Procedure
A 384-well plate was seeded with 10 µL per well of 0.25 µM peptide/QD
conjugates in water and in CSF. 2000 ng/mL, 200 ng/mL, 20 ng/mL, and 2 ng/mL
concentrations of active MMP-9 enzymes in water and the same concentrations in CSF
were prepared. The different MMP-9 dilutions in water were added in 10 µL quantities to
triplicate wells containing 10 µL of the peptide/QD conjugates in water, making 0.13 µM
peptide/QDs concentrations for every well. Likewise, the MMP dilutions in CSF were
added in 10 µL quantities to triplicate wells containing 10 µL of the peptide/QD
conjugates in CSF, also making 0.13 µM peptide/QD concentrations for every well. The
reagents were mixed by gently shaking the orbital plate for 30 seconds before being
placed into a CO2 incubator at 37 °C.

4.4.3 Results
Fluorescence measurements were made with the Tecan Infinite 200 PRO
Microplate Reader. The measurements were taken using 319 nm excitation and 595 nm
emission wavelengths with the optimized gain setting. The results shown in Figure 4.5
and Figure 4.6 reveal that the 9-AA peptide/QD conjugates showed moderate
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fluorescence sensitivity (no statistically significant change in fluorescence intensity as a
function of the active MMP-9 concentration) to active MMP-9 enzymes.
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Figure 4.5: Fluorometric responses to varying concentrations of active MMP-9 enzymes
from peptide/QD conjugates in water, using the 9 AA peptides, after 2 hours and 20
minutes of incubation at 37 °C.
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Figure 4.6: Fluorometric responses to varying concentrations of active MMP-9 enzymes
from peptide/QD conjugates in artificial CSF, using the +1 charge 9 AA peptides, after 2
hours and 20 minutes of incubation at 37 °C.

4.5 Characterization of ZnSe:Mn/ZnS QDs with negatively charged peptides
One possible reason for the lack of fluorescence sensitivity in the QD biosensors
to active MMP-9 enzymes is non-compatibility in protein-protein interaction. With
MMPs, there is an active Zn2+ region. The 9 AA cys-containing peptide, as was
determined from the Genscript Peptide Property Calculator, is basic and has a +1 charge
and an isoelectric point of 8.55 (the pH at which the surface charge of the molecule is
neutral). It is quite possible that the positively charged peptide repels the Zn-ion of the
active region of the MMP-9, and perhaps a negatively charged peptide should be
considered. The 14 AA cys-containing peptide
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({Glu}{Asp}{Glu}{Asp}{Glu}{Val}{Val}{Pro}{Leu}{Ser}{Leu}{Arg}{Ser}{Cys})
contains the MMP-9 cleavage motif but has additional negatively charged aspartic acid
{Asp} and glutamic acid {Glu} residues, making it acidic and more hydrophilic, giving it
a -4 charge, and an isoelectric point of 3.64. The 14 AA peptide also had the peculiar
property of having a QY that was higher than the QY of the remnant (4 AA) Peptide/QD
conjugates, in contrast to the fluorescence from the 9 AA Peptide/QDs being more
quenched than the 4 AA Peptide/QDs, as was discussed in Chapter 3.

4.5.1 Optical characterization
In order to verify the discovery that the 14 AA peptide/QDs are brighter than the
4 AA peptide/QDs, the bioconjugation protocol, as detailed in Chapter 3, was repeated,
twice, with the 14 AA peptides and the 4 AA peptides being conjugated to the QDs
separately and at the same time.
Keeping the peptide to QD ratio equal for both substrate and remnant peptides, 1
mg (6.3X10-4 mmol) of the 14 AA peptides (MW=1590.72) was conjugated to 1 mL of 1
µM ZnSe:Mn/ZnS QDs in 1:9 (v:v) benzylamine/DMF, and 0.3 mg (6.3X10-4 mmol) of 4
AA peptides (MW=477.58) were conjugated to 1 µM ZnSe:Mn/ZnS QDs in 1:9 (v:v)
benzylamine/DMF.
Immediately after bioconjugation, both substrate and remnant peptide/QDs were
subjected to 30 minutes of vortexing simultaneously. The reaction tubes were observed
under a black light, and indeed brighter fluorescence was observed for the 14 AA
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peptide/QDs conjugates, and significantly less fluorescence was seen for the 4 AA
peptide/QDs conjugates.
Figure 4.7 (a) is an image of the reaction tubes immediately after 30 minutes of
vortexing and (b) after 3 cycles of washing and 2 cycles of spin dialysis.

(a)

(b)

Figure 4.7: Results of simultaneous peptide/QD conjugation for (a) conjugates after
being vortexed simultaneously and (b) after washing and dialysis. In both figures the
sample on the left contains the QDs conjugated to the -4 charge 14 AA substrate
peptides, and the sample on the right contains QDs conjugated to the +1 charge 4 AA
remnant peptides. Note the obvious visual difference in fluorescence intensity.
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4.6 MMP-9 biosensing with negatively charged peptide
With the new interesting results regarding the fluorescence intensity difference
between the 14 AA and 4 AA, substrate and remnant respectively, peptide/QD
conjugates, the sensitivity of the negatively charged peptide/QD bioconjugates was
investigated. In addition, positive controls, remnant peptide/QD conjugates, were
included in the experiment. Also, the QD concentration was increased from 0.13 µM to
0.25 µM.

4.6.1 Materials
Active mouse MMP - 9 (Recombinant, Catalytic Domain) enzymes and assay
buffer solution (a component of the SensoLyte® 520 MMP - 9 Assay Kit) were purchased
from Anaspec. 384 well plates were purchased from Thermoscientific and artificial CSF
was purchased from Harvard Apparatus.

4.6.2 Procedure
A 384 well plate was seeded with 10 µL per well of 0.50 µM peptide/QD
conjugates in CSF. 10000 ng/mL, 1000 ng/mL, 100 ng/mL, 10 ng/mL, and 1 ng/mL
concentrations of active MMP-9 enzymes in CSF were prepared. The different MMP-9
dilutions in CSF were added in 10 µL quantities to triplicate wells containing 10 µL of
the peptide/QD conjugates in CSF, making 0.25 µM peptide/QDs concentrations for
every well. The reagents were mixed by gently shaking the orbital plate for 30 seconds
before being placed in a CO2 incubator at 37 °C.
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4.6.3 Results
Fluorescence measurements were made with the Tecan Infinite 200 PRO
Microplate Reader. The measurements were taken using 319 nm excitation and 595 nm
emission wavelengths with the optimized gain setting. Figure 4.8 reveals that the 14 AA
negatively charged peptide/QD conjugates show poor fluorescence sensitivity (very small
reduction in fluorescence intensity for active MMP-9 concentrations of 100 ng/mL and
above) to active MMP-9 enzymes. As expected, the positive control showed a much
lower signal, which implies that the 14 AA substrate peptides did not get cleaved.
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Figure 4.8: Fluorometric responses to varying concentrations of active MMP-9 enzymes
from peptide/QD conjugates in CSF, using the 14 AA peptides, after 1 hour of incubation
at 37°C.

Additionally, the procedure described in section 4.6.2 was repeated with the
peptide/QD conjugates dispersed into the assay buffer solution that came with the MMP68

9 assay package from Anaspec, as the assay buffer is supposed to provide the most ideal
conditions for the highest MMP-9 activity. However, the peptide/QD conjugates in the
assay buffer still lacked fluorescence sensitivity to MMP-9s, as can be seen from Figure
4.9.
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Figure 4.9: Fluorometric responses to varying concentrations of active MMP-9 enzymes
from peptide/QD conjugates in assay buffer, using the 14 AA peptides, after 1 hour of
incubation at 37°C.

4.7 MMP-9 biosensing with varying QD concentration
In light of the multiple biosensing trials being unable to produce any kind of
convincing MMP-9 detection, a different experiment was carried out, in which the
peptide/QD concentrations were varied. The idea behind this was to find a lower
concentration of biosensors that will be more comparable to the concentration of MMP9s, as it is possible that the high concentration of the peptide/QD conjugates
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overwhelmed the concentration of MMPs, preventing any noticeable change in
fluorescence.

4.7.1 Materials
Active mouse MMP - 9 (Recombinant, Catalytic Domain) enzymes were
purchased from Anaspec. 384 well plates were purchased from Thermo Scientific.

4.7.2 Procedure
Multiple dilutions of the 14 AA peptide/QD conjugates were prepared at
concentrations of 0.50 µM, 0.40 µM, 0.30 µM, 0.20 µM, 0.10 µM, and 0.05 µM in water.
Additionally, positive controls, 4 AA peptide/QD conjugates, were diluted to 0.25 µM,
0.20 µM, 0.15 µM, 0.10 µM, 0.05 µM, and 0.03 µM concentrations. MMP-9 enzymes
were diluted to 2,000 ng/mL in water. 10 µL of each 14 AA peptide/QD conjugate
concentration was mixed with 10 µL of 2,000 ng/mL MMP-9 enzymes in individual
wells in a 384-well plate, making concentrations of 0.25 µM, 0.20 µM, 0.15 µM, 0.10
µM, 0.05 µM, and 0.03 µM. Negative controls (14 AA peptide/QD conjugates without
MMP-9s) and positive controls (4 AA peptide/QD conjugates) were added to adjacent
wells at 0.25 µM, 0.20 µM, 0.15 µM, 0.10 µM, 0.05 µM, and 0.03 µM concentrations.
The reagents were mixed by gently shaking the orbital plate for 30 seconds before being
placed in a CO2 incubator at 37 °C for 1 hour and 39 minutes and again for an
accumulated time of 20 hours and 37 minutes.

4.7.3 Results
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Fluorescence measurements were made with the Tecan Infinite 200 PRO
Microplate Reader. The measurements were taken using 319 nm excitation and 595 nm
emission wavelengths with the optimized gain setting.
While the sensitivity was not high, the peptide/QD biosensors begin to show a
little fluorescence sensitivity to MMP-9 activity at 0.15 µM peptide/QD concentration
after 1 hour and 39 minute incubation time, and at 0.15 and 0.20 µM peptide/QD
concentrations after 20 hour and 37 minute incubation time. These results can be seen in
Figure 4.10 and Figure 4.11.
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Figure 4.10: Fluorescence-based biosensing of MMP-9, after 1 hour and 39 minutes of
incubation at 37 °C, with varying peptide/QD conjugate concentrations. 0.15 µM
concentration shows the most sensitivity to MMP-9.
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Figure 4.11: Fluorescence based biosensing of MMP-9, after 20 hour and 37 minutes of
incubation at 37 °C, with varying peptide/QD conjugate concentrations. 0.20 µM and
0.15 µM concentrations shows the most sensitivity to MMP-9. Note the decrease in
overall QD fluorescence from that of Figure 4.10.

4.8 MMP-9 biosensing with varying peptide concentration
It is speculated that the density of peptides on the surface of the QDs was perhaps
too high, resulting in a steric hindrance that would be harming the sensitivity of the
MMP-9 biosensor. As a result, experiments were conducted in which peptides, both
remnant and substrate, were conjugated to the surfaces of QDs at 33% and 66% of their
usual concentrations. The PL behavior of the 14 AA peptide/QD conjugates for 33% and
66% peptide concentration indicates consistent behavior with that of previous 100%
peptide concentration, as can be observed in Figures 4.12, 4.13, 4.14, 4.15, 4.16, and
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4.17, with the exception that the degree of quenching was less for 66% and even less for
33% samples.
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Figure 4.12: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 33% substrate polypeptide, using 588 nm and 309 nm for parked emission
and excitation wavelengths respectively.
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Figure 4.13: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 33% remnant polypeptide, using 588 nm and 309 nm for parked emission
and excitation wavelengths respectively.
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Figure 4.14: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 66% 14 AA substrate polypeptide, using 588 nm and 309 nm for parked
emission and excitation wavelengths, respectively.
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Figure 4.15: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 66% remnant polypeptide, using 588 nm and 309 nm for parked emission
and excitation wavelengths, respectively.
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Figure 4.16: (a) Excitation and (b) emission spectra for colloidal peptide/QD
conjugates in CSF with 100% 14-AA substrate polypeptide, using 589 nm and 314
nm for parked emission and excitation wavelengths, respectively.
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Figure 4.17: (a) Excitation and (b) emission spectra for colloidal peptide/QD
conjugates in CSF with 100% remnant polypeptide, using 596 nm and 317 nm for
parked emission and excitation wavelengths, respectively.
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4.8.1 Materials
Active mouse MMP - 9 (Recombinant, Catalytic Domain) enzymes were
purchased from Anaspec. 384 well plates were purchased from Thermo Scientific.

4.8.2 Procedure
Remnant and substrate 14 AA substrate peptide/QD conjugates were synthesized
according to the bioconjugation procedure detailed in Chapter 3, with the exception that
the peptides were conjugated to the QDs at 33% and 66% of their usual concentration,
with the intention that the conjugated peptides at the surface of the QDs would have a
lower surface density.
A 384 well plate was setup with triplicate wells for 0.25 µM QDs with 33% and
66% of original peptide coating for both 14-AA substrate and remnant peptides. The QD
biosensors were incubated with MMP-9 at 1 µg/mL concentration in CSF for 1 hour.

4.8.3 Results
Fluorescence measurements were made with the Tecan Infinite 200 PRO
Microplate Reader. The measurements were taken using 309 nm excitation and 588 nm
emission wavelengths with the optimized gain setting.
The results are shown in Figure 4.18. For the first time, the 66% peptide/QD
conjugates show a statistically significant (p=0.04) response to active MMP-9. However,
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the response is an increase in fluorescence rather than a decrease, as the positive controls
would lead one to believe.
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Figure 4.18: Fluorometric responses to 1 µg/mL of active
MMP-9 in CSF for 66% 14-AA peptide/QD conjugates and
33% 14-AA peptide/QD conjugates.

4.9 MMP-9 biosensing with dilute peptide concentrations
Indeed, as the results from Figure 4.18 suggest, steric hindrance may have been a
primary cause for the lack of an MMP-9 sensing signal. 66% peptide/QD conjugates were
beginning to show an increased signal; therefore, further experimentation was explored in
which peptides, both remnant and substrate were conjugated to the surfaces of QDs at
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10%, 1%, and 0.1% of their usual concentrations. The QD concentration for this
experiment was 0.25 µM.
Figures 4.19, 4.20, 4.21, 4.22, 4.23, and 4.24 are the PLE and PL for 10%, 1%,
and 0.1% peptide/QD conjugates, which do not indicate much of a change in PL intensity
between substrate and remnant peptides, as peptide densities on the surface of the QDs
have become very low at this point.
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Figure 4.19: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 0.1% 14-AA substrate polypeptide, using 588 nm and 319 nm for parked
emission and excitation wavelengths, respectively.
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Figure 4.20: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 0.1% 14-AA remnant polypeptide, using 588 nm and 319 nm for parked
emission and excitation wavelengths, respectively.
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Figure 4.21: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 1% 14-AA substrate polypeptide, using 588 nm and 319 nm for parked
emission and excitation wavelengths, respectively.
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Figure 4.22: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 1% remnant polypeptide, using 588 nm and 319 nm for parked emission and
excitation wavelengths, respectively.
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Figure 4.23: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 10% 14-AA substrate polypeptide, using 588 nm and 319 nm for parked
emission and excitation wavelengths, respectively.
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Figure 4.24: (a) Excitation and (b) emission spectra for colloidal peptide/QD conjugates
in CSF with 10% remnant polypeptide, using 588 nm and 319 nm for parked emission
and excitation wavelengths, respectively.

4.9.1 Materials
Active mouse MMP - 9 (Recombinant, Catalytic Domain) enzymes were
purchased from Anaspec. 384 well plates were purchased from Thermo Scientific.

4.9.2 Procedure
Remnant and substrate peptide/QD conjugates were synthesized according to the
bioconjugation procedure detailed in Chapter 3, with the exception that the peptides were
conjugated to the QDs at 0.1%, 1%, and 10% of their usual concentration.
A 384-well plate was setup with triplicate wells for 0.25 µM QDs with 0.1%, 1%,
and 10% of original peptide concentration for both 14-AA substrate and remnant
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peptides. The QD biosensors were incubated with MMP-9 at 5µg/mL concentration in
CSF for 4 hours.

4.9.3 Results
Fluorescence measurements were made with the Tecan Infinite 200 PRO
microplate reader. The measurements were taken using 319 nm excitation and 588 nm
emission wavelengths, with the optimized (255%) gain setting.
The results are shown in Figure 4.25. For 1% and 10% peptide/QD conjugates it
does not appear to be a discernable signal between 0 and 5 µg/mL active MMP-9
concentration. However, similar to the results for the 66% peptide/QD conjugates in
Figure 4.18, it would seem that the signal increases due to the presence of MMP-9s for
0.1% peptide/QD conjugates.
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Figure 4.25: Fluorometric responses to 5 µg/mL of active MMP-9 in CSF for 0.1% ,1%,
and 10% peptide/QD conjugates, after 4 hours of incubation.
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4.10 Summary
The 14 AA peptide/QD conjugate biosensors show slight sensitivity to 1000
µg/mL MMP-9s in water at 0.15 µM concentration for 1 hour and 39 minute incubation
time, while the biosensors show sensitivity at 0.20 µM and 0.15 µM concentrations after
incubating overnight. It is likely that lower concentrations of the biosensors would show
sensitivity to 1000 µg/mL MMP-9s, but, after observing Figure 4.10 and Figure 4.11,
the biosensors become too dilute for their fluorescent signals to rise above noise level.
In addition, the peptides were diluted, decreasing peptide surface density on the
QDs, in order to account for the possibility of steric hindrance. Out of the several
dilutions tested, 66% and 0.1% (of normal peptide concentration) show a slightly
increased fluorescence signal, in contrast to the positive control remnant peptide/QD
conjugates, which usually display lower concentration. Nonetheless, the 14-AA substrate
peptide/QD conjugates show some sensitivity to active MMP-9 at 66% and 0.1% peptide
concentrations.
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Chapter 5
Linking ZnSe:Mn/ZnS quantum dots to silica
5.1 Silica surface modification
In order to covalently bond the synthesized Mn-doped ZnSe/ZnS QDs to a SiO2
surface for the intended application of optical fiber based MMP biosensing, a silane
coupling agent (SCA), 3-mercaptopropyltrimethoxysilane (MPTMS), was used to create
a thiol monolayer over SiO2 microscope slides. Due to the thiol-metal affinity, it was
observed that QDs could be covalently bonded to the thiol groups at the surface of the
SiO2.
SCAs generally contain an organofunctional group, a linker, a Si atom, and
hydrolyzable groups, generally three alkoxy groups bonded to the Si atom, Figure 5.1.

Hydrolyzable
groups

Silicon atom Linker Organofunctional
group

Figure 5.1: The silane coupling reagent MPTMS and the characteristic components of a
silane coupling agent.

After hydrolysis of the hydrolyzable groups in a SCA, a reactive silanol is formed
that can react with hydroxyl (OH) groups to form stable oxane bonds; and so a monolayer
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of MPTMS can be formed over OH-modified silica, thus resulting in silane covalently
bonded to silica with the thiol molecules at the surface38.
Figure 5.2 (a) – (d) is a schematic diagram illustrating the chemistry of
functionalizing silica with an SCA. Initially hydrolyzable regions of the SCA undergo
hydrolysis in the presence of water, forming OH groups, Figure 5.2(a). Following
hydrolysis, the compound becomes reactive and the silanol molecules condense together,
Figure 5.2(b). In the presence of OH modified silica, the OH groups of the polymerized
SCA form hydrogen bonds with the OH groups on the silica, resulting in a SCA
monolayer over the silica surface, Figure 5.2(c). Finally, after applying heat and
dehydrating the compound, stable covalent bonds form in place of the hydrogen bonds,
Figure 5.2(d).
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(a)

(b)

(c)

(d)

Figure 5.2: Illustration of the different processes that take place during SCA
modification of silica: (a) hydrolysis, (b) condensation, (c) hydrogen bonding, and (d)
bond formation39.

SCAs can have different functional groups, and in MPTMS SH is the functional
group. A monolayer of MPTMS, attached to silica at the hydrolyzable region, will have
the SH functional group at the outer most surface. Due to the aforementioned metal
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affinity from the thiol molecules, MPTMS can work as a linker for covalently bonding
ZnSe:Mn/ZnS QDs to silica, figure 5.3.

Figure 5.3: Illustration of a tethered QD covalently linked to the SH group in MPTMS
modified silica.

5.2 Silica modification processes
In this work, two different procedures were developed to attach the QDs to silica.
The first process (Procedure 1) involves functionalizing the silica with MPTMS first
before dropping the QDs over the functionalized silica. The second process involves
coating the QDs with MPTMS first and then dropping the coated QDs onto silica. The
second procedure (Procedure 2) works better, as the fluorescence from the QDS on silica
could still be detected, whereas in the first procedure the QDs only show a weak
absorption signal and no fluorescence at all.
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5.2.1 Materials
Silica glass microscope slides with frosted ends were purchased from Corning.
Hydrogen Peroxide was purchased from EMD. 99% 3-mercaptopropyltrimethoxysilane
(MPTMS) was purchased from Gelest. 95%-97% sulfuric acid, 99.8% benzene,
chloroform, and 99.9% methanol was purchased from Sigma Aldrich. 70% nitric acid
was purchased from General Chemical.

5.2.2 Procedure 1
The procedure to modify silica with OH and MPTMS was modified from Hu et al
200140. The procedure to covalently bond ZnSe:Mn/ZnS QDs to MPTMS modified silica
was developed in house.
For OH modification, the non-frosted portion of the glass slide was submerged
into 1 N HNO3 solution in a glass staining jar for 24 hours. In order to increase OH
concentration, the slide was taken out of the nitric acid, rinsed with DI water, and
submerged in 1:3 H2O2 in H2SO4 (piranha solution) for 30 minutes at 70 °C. Following
piranha treatment, the glass slide was rinsed with DI water, dried with an N2 blower, and
further dried for 30 minutes in an oven at 100 °C.
Inside an Ar-filled glovebox, the OH-modifies glass slide was submerged in a
solution mixture of 0.25g of MPTMS in 20 mL of benzene for 30 minutes. The MPTMS
modified slide was rinsed with benzene, chloroform, methanol, and DI water before
being dried with an N2 blower. The MPTMS modified plate was dehydrated in an oven
for 30 minutes at 100 °C.
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The MPTMS plate was placed in a petri dish over a cloth soaked in either
chloroform or toluene (depending on the solvent the QDs are in). The QDs were dropped
over the silica plate until the surface of the plate was covered with the colloidal QD
solution. The setup can be seen in figure 5.4. Subsequently, the petri dish containing the
silica plate was covered on placed on a Barnstead/Lab-Line Lab-Rotator (orbital shaker)
at a gentle shaking speed (not enough to cause the solution to fall off the plate, but to roll
over it gently) for 2 hours.

Figure 5.4: Setup of colloidal QD solution on glass slide in petri dish over solvent
soaked cloth. The soaking of the cloth in solvent prevents evaporation of the colloidal
solution when the petri dish is covered with a lid.

The plate was rinsed thoroughly with chloroform or toluene (depending on the
solution the QDs are in).
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5.3 Optical characterization (Procedure 1)
Unfortunately with procedure 1, no QD fluorescence could be detected while
making measurements in a HoribaJobanYvon Fluorolog-spectrofluorometer. Without
fluorescence, UV-Vis absorption from a Varian Cary spectrophotometer was used to
verify that the QDs stayed attached as a result of thiol binding after washing the slide
with toluene. The absorption properties of glass slides were measured for the QDmodified slide, a blank slide (not treated with piranha or OH-modified), and a control
slide, and the QD-modified slide minus the blank slide, subtracting the absorption
contribution from the silica substrate. Figure 5.5 shows the absorption spectrum for Mndoped ZnSe/ZnS QDs in toluene, where an absorption feature can be observed at 423 nm.
The absorption measurements taken from a blank slide and the QD-modified slide can be
seen in figure 5.6. The absorption feature at 423 nm can be observed for the QDmodified slide but not for the blank slide. Furthermore, in figure 5.6, the 423 nm
absorption feature can be observed more clearly in the absorption spectra for the QDmodified slide with the absorption line of the blank slide subtracted out.
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Figure 5.5: UV-Vis absorption measurement for
ZnSe:Mn/ZnS QDs in toluene with an absorption feature at
~423 nm.
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Figure 5.6: UV-Vis absorption measurements for the QD-modified
(blue), the blank (brown), and QD-modified minus the blank slide
(black).
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5.4 QD pre-modification
With the failure to produce fluorescently active QDs covalently bonded to the
surface of silica, a new method of initially coating the QDs with MPTMS was
implemented (Procedure 2). Figure 5.7 is an illustration of an MPTMS coated
ZnSe:Mn/ZnS QD. Since the QDs were coated with MPTMS first, the silica was made
only to be OH-modified without MPTMS modification. After orbital shaking the QDs
onto the silica and thoroughly washing the slides with chloroform, the QDs on the silica
maintained their fluorescence. In order to have increased silica surface area, the frosted
portion of the silica slide was treated and modified with QDs.

MPTMS surface
coating

ZnS shell

Un-doped ZnSe
layer

Figure 5.7: Illustration of the MPTMS coated ZnSe:Mn/ZnS QD nanocomposite. The QD
is coated partially with MPTMS so it can bond to silica and still have conjugation sites
available for cys-peptides.
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5.4.1 Procedure 2
The frosted portion of the silica slide was OH-modified the same way as in
procedure 1. The procedure to coat ZnSe:Mn/ZnS QDs with MPTMS was adapted from
Garcia-Cerda et al 201041.
In an N2 filled glovebox, MPTMS was mixed with 2 mL of ZnSe:Mn/ZnS QDs in
chloroform at a 1:1 mass ratio (in this case 11.45 mg MPTMS/11.45 mg QDs). The
mixture was placed into a 25 mL three-neck flasks, capped with two rubber septa on the
outer necks and a condenser and nitrogen adaptor on the center neck. The three-neck
flask reaction apparatus was removed from the glovebox and put under N2 by connecting
it to the Schlenkline gas-manifold. With water flowing through the condenser, the
solution was heated to a reflux temperature (54.6 °C) and stirred for 6 hours. After the
reaction, the solution was cooled to room temperature and purified through centrifugation
with acetone. The MPTMS modified QDs were dispersed in 2 mL of chloroform and
stored in a vial.
The MPTMS coated QDs were shaken onto the OH-modified silica similar to that
described in procedure 1. The slide was placed on a chloroform soaked cloth in a petri
dish. The colloidal QDs were dropped onto the slide in chloroform until the entire frosted
portion of the slide surface was covered with solution. The petri dish was covered and the
solution was gently shaken with the orbital shaker, just enough to smoothly flow the
solution over the slide without spilling over, for two hours. Afterwards, the QD-modified
silica slide was dried at low heating temperature and then baked in an oven at 120 °C for
30 minutes to dehydrate the MPTMS linker and form covalent bonds between the linker
and the silica.
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5.5 Optical characterization (Procedure 2)
While Procedure 1 produced QD-modified slides without visible fluorescence,
Procedure 2 produces QD-modified slides with visible QD fluorescence. Figure 5.8 (a) –
(c) are images of the QDs on silica after orbital shaking. Figure 5.8 (a) is an image of the
QD modified slide immediately after baking it in the oven. Figure 5.8 (b) is an image of
the slide after thoroughly washing the slide in chloroform, and figure 5.8 (c) is the slide
with a small section cut off for PL and QE characterization.

(a)

(b)

(c)

Figure 5.8: (a) the ZnSe:/Mn/ZnS QD modified silica after baking at 120 °C in the oven
for 30 minutes, (b) the QD modified silica after being thoroughly washed with
chloroform, and (c) a small section of the glass slide cut out for characterization. The
characteristic orange 598 nm Mn emission can be clearly seen in the images.
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5.5.1 Photoluminescence
The QD modified silica was characterized for PLE, PL, and QE with a
HoribaJobanYvon Fluorolog-3 spectrofluorometer. Figure 5.9 (a) and (b) are the PLE
and PL, respectively, for ZnSe:Mn/ZnS QDs on silica, as prepared by Procedure 2. The
parked emission wavelength for the PLE measurement was 598 nm, and the parked
excitation wavelength for the PL measurement was 380 nm. The PLE spectrum in Figure
5.9 (a) shows an increase in intensity at wavelengths below 380 nm, but at lower
wavelengths the glass would begin to show a fluorescence peak. The QE for the emission
seen in Figure 5.9 (b) turned out to be 8%. The spectral slit widths for the PL
measurements were 1 nm for both excitation and emission.
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Figure 5.9: (a) PLE and (b) PL spectrum for ZnSe:Mn/ZnS QD modified silica with
598 nm parked emission for PLE and 380 nm parked excitation for PL.

5.6 Absorption spectra for QD supernatant
It is important that the QDs are only partially coated in MPTMS so that there are
still bioconjugation sites available for the peptides. In order to verify partial coating the
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presence of MPTMS in the supernatant from the centrifugation step was analyzed via
near-IR absorption from a Varian Cary spectrophotometer. First the near-IR absorption
spectrum was measured for pure MPTMS in order to note any absorption features that
MPTMS might have. Taking note of the MPTMS absorption features, the absorption
spectrum of the reaction supernatant was measured and no MPTMS features are
identified. The idea is that if MPTMS is still detected in the supernatant then it is likely
that the QD surfaces are saturated with MPTMS. Since no MPTMS absorption features
show up on the measured spectrum, it is likely that the QDs are not saturated with
MPTMS and open surface area is open for peptide bioconjugation for the biosensing
application of these QDs. Additionally, the near-IR absorption spectrum for the partially
MPTMS coated QDs was measured, and incidentally no MPTMS features show up
either. Figure 5.10 is a near-IR absorption plot of MPTMS, the MPTMS coated QDs, and
the reaction supernatant. However, as was illustrated in Figure 5.2, through the
modification process, MPTMS undergoes hydrolysis, condensation, and dehydration
before being applied to a surface, the QD surface in this case, and might suggest a
different near-IR absorption spectrum.
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Figure 5.10: Near-IR absorption spectrum for MPTMS (red), MPTMS coated
ZnSe:Mn/ZnS QDs (purple), and supernatant (blue).

5.7 Summary
It would seem that with the methods applied, coated the QDs with MPTMS first
(Procedure 2) is significantly more affective at attaching these QDs to silica, and
maintaining their fluorescence, than coating the silica with MPTMS first (Procedure 1).
The fluorescently active QDs covalently bonded to silica are not as bright as the colloidal
QDs, yet the brightness thus achieved has been satisfactory. A lack of MPTMS
absorption features from the supernatant suggests partial MPTMS coating on the QDs. As
for attaching the QDs to the tips of silica optical fibers, a different lab procedure using
the same chemistry presented herein can be applied.
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Chapter 6
Macrophage cytotoxicity studies with peptide coated Mn-doped ZnSe/ZnS
quantum dots
6.1 in vivo QD potential and inherent cytotoxicity
A particular interesting prospect has been the use of QDs for in vivo applications,
such as imaging, biomarkers, and drug and disease treatment development. The high
stability, large stokes shifts, and high absorptivity coefficients of QDs make them more
suitable for complex in vivo conditions42, 43. As such, QDs are ideal candidates for
advancements in the biomedical field44 with a high potential that has generated a lot of
worldwide attraction in the field of research, and as a result, numerous methods have
been developed to try and utilize QDs to their fullest extent. QDs are widely known for
their contribution to biosensing and tracking, cellular imaging, tissue staining, and other
in vivo and in vitro research and diagnostic purposes45.
However, it is paramount for the benefits of engineered nanoscale products to
outweigh their toxicity, which poses potential risks to human health. Numerous studies
provide evidence that QD toxicity is a complex issue that depends not only on diversity
of their individual physicochemical properties, core and shell materials, size, charge, dose
(concentration), functional groups of the cap, but also on their mechanical, photolytic and
oxidative stability in different environments46. For instance, the toxicity associated with
conventional semiconductor II-IV series, zinc sulfide (ZnS), zinc-selenide (ZnSe),
cadmium selenide (CdSe), and cadmium telluride (CdTe) QD cores in leaching of
primary core components of the QDs: cadmium (Cd), tellurium (Te), and selenium (Se)
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into surroundings upon oxidation or photolysis and damage of the shell. Heavy metal Cd
ions are infamously known to be toxic to animal and human cells47, 48, 49.
Therefore, for a comprehensive evaluation of toxicity of each QD type tailored for a
specific application separate testing should be performed for any particular cell type,
organism and route of administration.
Research shows that toxicity varies based upon the amount of QD dosage. In the case
of maltodextran-coated CdS QDs, the borderline between toxic and non-toxic is shown to
be less than 3.28 nM, but not any greater than 4.92 nM50. Based off of their inherent
toxicity, scientists have attempted to change the components of the QDs to make them
more biocompatible. A potential solution is to avoid the use of heavy metals, such as
lead, mercury, and cadmium and instead use transition metals3. Replacing the Cd
component with Zn in ZnSe doped with Mn ions, or CdTe capped with SiO2 has been
proven to be fairly efficient in reducing QD toxicity4. Other options include QDs capped
with L-glutathione (GSH) and thioglycolic acid (TGA) that have allowed the QDs to be
more tolerable in vivo51.
Zn has much lower toxicity than Cd. However, some materials, which may not be
toxic in their bulk form, might in fact be toxic at the nano scale. Since the QD-based
MMP biosensor will ultimately be placed inside the spinal column of the human body, it
becomes necessary to assess potential QD toxicity. In order to characterize the cytotoxic
potential of peptide coated Mn-doped ZnSe/ZnS core/shell QDs on human cells, the
ApoTox-Glo Triplex assay (Promega) was used. Macrophage cells were chosen for
evaluation of QD cytotoxicity based on several reasons. First, resident macrophages (MF)
of the brain and spinal cord, or microglia, come into direct contact with foreign
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molecules, including QDs (and phagocytose them), therefore acting as the first and main
form of active immune defence in the CNS. And second, MF are capable of releasing
MMPs, which are responsible for cleaving the peptides conjugated to the QDs, and as a
result mimicking the real life situation of peptide/QD exposure to the insides of the spinal
column.

6.2 The ApoTox-Glo® Triplex assay
The chosen assay can provide information regarding cytotoxicity, viability, and
apoptosis effects that the material under test has on the cells. The degree of cytotoxicity,
viability, and apoptosis was measured using substrates, which when cleaved by
appropriate enzymes induce quantifiable light signal that can be measured with a plate
reader. The assay’s reagents include solutions of substrates that release fluorescent
molecules when cleaved by protease enzymes for live and dead cells. The substrate,
glycyl-phenylalanyl-aminofluorocoumarin (GF-AFC), enters live cells and is cleaved by
protease enzymes to release the florescent AFC. The intensity of AFC fluorescence is the
indicator of cell viability. Another substrate, bis-alanylalanyl-phenylalanyl-rhodamine
110 (bis-AAF-R11O), does not enter live cells and is cleaved by dead cell proteases,
releasing a fluorescent substance known as R110. The intensity of the R11O fluorescence
is the indicator of cell cytotoxicity. To measure apoptosis, the Caspase-Glo 3/7 reagent
consisting of a caspase substrate in solution will result in a luminescent signal upon
cleavage, a signal proportional to the degree of apoptosis taking place during treatment.
The QDs under test are of interest for in vivo biosensing applications and
therefore must display very little cytotoxicity, if any. In this chapter, the low cytotoxic
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properties of peptide coated Mn-doped ZnSe/ZnS non Cd containing QDs at low
concentrations, particularly ˂ 25 µM (1.2 mg/mL), are reported.

6.3 Procedures
6.3.1 Materials
Murine macrophage RAW 264.7 cells were purchased from ATCC, DMEM cell
media was purchased from Life Technologies. The ApoTox-Glo® Triplex assay kit was
purchased from Promega. Digitonin, ionomycin, and staurosporine were purchased from
Sigma-Aldrich. 384 well plates were purchased from Thermo Scientific.

6.3.2 Cell Preparation
The cell cultures were prepared using 4 different 384 well-plates seeded with
mouse macrophage cells at a concentration of 5,000 cells per well in DMEM cell media
containing 10% fetal bovine serum and 1% penicillin/streptomycin. Each of the four
wells corresponded to 6, 12, 24, and 48 hour incubation treatments, with triplicate wells
set up for the 6 hour treatment and hextuplicate wells for the 12, 24, and 48 hour
treatments.

6.3.3 ZnSe:Mn/ZnS QD synthesis
The QDs were synthesized as detailed in chapter 2.
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6.3.4 QD bioconjugation
Cysteine containing peptides were conjugated to the ZnSe:Mn/ZnS QDs as
detailed in chapter 3.

6.3.5 Cytotoxicity, viability, and luminescence assay
The ApoTox-Glo® Triplex assay kit was purchased from Promega. For the
testing, the QD bioconjugates were incubated with the cells at 0.2500, 0.1250, 0.06250,
and 0.03125 µM concentrations for each treatment. Each individual well consisted of 20
µL total volume of solution with 10 µL of cells in cell media and 10 µL of QDs in water.
Background measurements were taken and subsequently subtracted from every average
reading. As a control, measurements involving untreated cells were included. Positive
controls include treatments from 2 compounds known to be toxic, digitonin and
ionomycin (markers for cytotoxicity and necrosis, respectively), as well as staurosporine,
a compound known to induce apoptosis. The concentrations for the positive controls were
15 µg/mL for digitonin (15 minute incubation time) used for the 6 hour treatment, 30
µg/mL for digitonin (25 minute incubation time) used for the 12, 24, and 48 hour
treatments, 100 µM for ionomycin (6 hour incubation time) used for all four treatment
times, and 10 µM for staurosporine (6 hour incubation time) used for all treatment times.
Measurements were taken with a Tecan Infinite 200 PRO Microplate Reader,
measuring fluorescence from the bottom of the well plate.
Cytotoxicity/viability reagents were added to the wells immediately after the
incubation period, and following a brief mixing in an orbital shaker for 30 seconds, the
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plate was incubated for 30 minutes before plate measurements were taken. Viability
measurements were taken using 400 nm excitation wavelength and 505 nm emission
wavelength for all 4 treatment times (6, 12, 24, and 48 hours). Cytotoxicity
measurements were taken using 485 nm wavelength excitation and 520 nm emission
wavelength. The caspase reagent was added last to every well and was briefly mixed with
an orbital shaker for 30 seconds and then incubated for 30 minutes, before measurements
were taken with the plate reader.

6.4 Results
6 Hour Incubation Time: Figure 6.1 shows that the viability of the cells were
affected by all three positive controls, most particularly 60% lower viability from
Ionomycin (p=0.0002 << 0.01) and 51% lower viability by staurosporine (p=0.0002 <<
0.01), and to a smaller extent by 16% from digitonin (p=0.069). However, none of the
QD concentrations showed any appreciable difference or statistical significance when
comparing the QD treated cells with the untreated cells, indicating that there is no
viability effect on the cells from the QDs at six hours.
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Figure 6.1: Macrophage cell viability bar graph depicting the cytotoxic effect of
Mn-doped ZnSe/ZnS peptide coated QD from a six-hour treatment on macrophage
cells. Results are in expressed in mean + s.d., n=3. UTC – untreated cells, N.S. –
not significant, RFU – relative fluorescence units.

Likewise, in Figure 6.2, there is no real difference between the cytotoxicity from
the QDs in relation to the untreated cells even taking into account relatively large
standard deviations on some fraction of the data. Though in this case, higher intensity
indicates a higher cell death, and a significantly higher intensity could be observed in the
positive controls, a 119% increase in cell cytotoxicity for digitonin (p=0.059), a 429%
increase for staurosporine (p=0.0009 << 0.01), and a 452% increase for ionomycin
(p=0.002 < 0.01). Despite the fact that digitonin was intended to indicate cytotoxicity,
both staurosporine and ionomycin received higher intensity levels, all three were
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significantly more toxic than any of the QD concentrations or the untreated control. No
QD concentrations from the 6 hour cytotoxicity test showed any statistically significant
increases in cell cytotoxicity.
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Figure 6.2: Macrophage cell cytotoxicity bar graph depicting the cytotoxic
effect after a six hours treatment of Mn-doped ZnSe/ZnS peptide coated QDs on
macrophage cells in cell media. Results are in expressed in mean + s.d., n=3.
UTC – untreated cells, N.S. – not significant, RFU – relative fluorescence units.

Figure 6.3 shows the luminescence results from 6 hour incubation in which
induced apoptosis was quantified. The cells treated with staurosporine, the positive
control for induced apoptosis, show a 607% higher signal (p=0.00002 <<< 0.01) than that
of the untreated cells. A small sign of induced apoptosis can be seen from the
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luminescent signal from the cells treated with 0.25 µM QDs, with a 96% increase in
luminescence (p=0.00009 <<<0.01) from that of the untreated cells.
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Figure 6.3: Macrophage cell induced apoptosis bar graph depicting induced
apoptosis after a six-hour treatment of Mn-doped ZnSe/ZnS peptide coated QDs on
macrophage cells in cell media. Results are in expressed in mean + s.d., n=3. ∆
p=0.0005 (<0.01), ∆∆ p=0.0004 (<0.01), and ∆∆∆ p=0.00009(<<0.01). UTC –
untreated cells, N.S. – not significant, RLU – relative luminescence units.

12 Hour Incubation Time: It can be seen from Figure 6.4 that cell viability starts
to become an issue at the 12 hour incubation time, which scales inversely with
concentration. The fluorometric response with regards to cell viability, when compared
with the untreated cells, decreases by 50% (p=0.0000007 <<< 0.01) for 0.25 µM QDs,
19% (p=0.001 < 0.01) for 0.13 µM QDs, 13% (p=0.005 < 0.01) for 0.06 µM QDs, and
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8% (p=0.009 < 0.01) for 0.03 µM QDs. All three positive controls decrease significantly
in comparison to the untreated by 62% (p=0.000000003 <<<0.01) for digitonin, 48%
(p=0.000000006 <<< 0.01) for staurosporine, and 65% (p=0.0000000003 <<< 0.01)) for
ionomycin. Of interesting note is how comparable the 0.025 µM QDs signal is to that of
the positive controls.
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Figure 6.4: Macrophage cell viability bar graph depicting the cytotoxic effect of
Mn-doped ZnSe/ZnS peptide coated QD from a twelve-hour treatment on
macrophage cells. Results are in expressed in mean + s.d., n=6. * p=0.009
(<0.01), ** p=0.005 (<0.01), *** p=0.001 (<0.01), **** p=0.0000007
(<<<0.01). UTC – untreated cells, N.S. – not significant, RFU – relative
fluorescence units.
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Figure 6.5 shows cytotoxicity results for 12 hour treatments. The three positive
controls display a significantly higher fluorescent response in comparison to the
untreated, particularly a 1319% increase (p=0.00000003 <<< 0.01)) with digitonin and a
1370% increase (p=0.000000003 <<< 0.01) with ionomycin, and a smaller but still
statistically significant 360% increase (p=0.0000013 <<< 0.01) with staurosporine.
Conflicting with the viability data from Figure 6.4, it would seem that the signals from
three of the four QD concentrations show no statistically significant variability for
cytotoxicity, with 0.13 µM QD having a 70% increase (p=0.009 < 0.01) over the
untreated, which is drastically lower than the positive control signals.
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Figure 6.5: Macrophage cell viability bar graph depicting the cytotoxic effect of Mndoped ZnSe/ZnS peptide coated QD from a twelve-hour treatment on macrophage
cells. Results are in expressed in mean + s.d., n=6. † p= 0.009 (<0.01). UTC –
untreated cells, N.S. – not significant, RFU – relative fluorescence units.

With Figure 6.6, a small degree of induced apoptosis is seen from the 0.25 µM
QDs with a 96% signal increase from that of the untreated cells, while none of the other
three concentrations show any statistically significant variation in luminescence. The
96% increase is minor when compared to the 1149% signal increase (p=0.00000000009
<<< 0.01) from the staurosporine control.
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Figure 6.6: Macrophage cell induced apoptosis bar graph depicting induced
apoptosis after a twelve-hour treatment of Mn-doped ZnSe/ZnS peptide coated QDs
on macrophage cells in cell media. Results are in expressed in mean + s.d., n=6. ∆
p=0.00000002 (<<<0.01). UTC – untreated cells, N.S. – not significant, RLU –
relative luminescence units.

24 Hour Incubation Time: As seen from the 24 hour viability data in Figure 6.7,
the fluorometric response of digitonin was 30% that of the untreated cells (p=0.0013 <
0.01). Staurosporine shows a 60% (p=0.000000008 <<< 0.01) decrease in viability from
that of the control. Likewise, the ionomycin shows a 52% decrease in viability
(p=0.0000000003 <<< 0.01). The 50% decrease in viability of the highest QD
concentration shown in the 12 hour trial is seen here as well (p=0.00000005 <<< 0.01)
with viability as a whole continuing to scale inversely for 0.03 µM with 94% of the
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untreated, 0.06 µM with 85% of untreated and 0.13 µM with 77% of the untreated,
(p=0.1, p=0.002 < 0.01 and p=0.0002 << 0.01, respectively). This indicates a decrease in
viability of the QDs during a 24 hour treatment for the 0.25 µM concentration, almost
equal with that of the positive controls.

15000
14000
13000

Viability Fluorescence [RFU]

12000

UTC
0.03 µM QD
0.06 µM QD
0.13 µM QD
0.25 µM QD
Digitonin
Staurosporine
Ionomycin

11000
10000
9000

***

8000
7000

*

**

N.S.

6000
5000
4000
3000
2000
1000

Figure 6.7: Macrophage cell viability bar graph depicting the cytotoxic effect of Mndoped ZnSe/ZnS peptide coated QD from a twenty-four hour treatment on
macrophage cells. Results are in expressed in mean + s.d., n=6. * p=0.002 (<0.01),
** p=0.0002 (<<0.01), *** p=0.00000005 (<<<0.01). UTC – untreated cells, N.S.
– not significant, RFU – relative fluorescence units.
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In Figure 6.8, ionomycin showed particularly strong cytotoxic effects with an
increase in fluorometric intensity of 1,739% over the untreated cells
(p=0.0000000000005 <<< 0.01) with staurosporine increasing over the untreated control
by 795% (p=0.00000003 <<< 0.01) and digitonin by 846% (p=0.0000002 <<< 0.01).
0.25 µM QDs show an increase of 315% over the untreated control, and though, it is
statistically significant (p=0.000003 <<< 0.01) this is significantly less than the positive
controls. All other QD concentrations, however, show no statistical deviation from the
fluorometric intensity of the untreated cells.
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Figure 6.8: Macrophage cell viability bar graph depicting the cytotoxic effect of Mndoped ZnSe/ZnS peptide coated QD from a twenty-four twelve-hour treatment on
macrophage cells. Results are in expressed in mean + s.d., n=6. † p=0.03 (<0.05), ††
p=0.000003 (<<<0.01). UTC – untreated cells, N.S. – not significant, RFU – relative
fluorescence units.
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In testing luminescence at 24 hours in Figure 6.9, the intended control,
staurosporine, shows greater levels of apoptosis than any other substance tested, with an
increase of 306% (p=0.0000002 <<< 0.01) over the untreated control, though the other
two positive controls are nearly as fluorometrically intense, with digitonin increasing
apoptosis by 192% (p=0.0002 << 0.01) and ionomycin increasing apoptosis by 76%
(p=0.0002 << 0.01). However, the 0.25 µM QDs showed an elevation of 219%
(p=0.000002 <<< 0.01). None of the other QD concentrations show a large increase in
apoptosis (though the 0.03 µM shows a significant decrease, it is within the margin of
error).
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Figure 6.9: Macrophage cell induced apoptosis bar graph depicting induced
apoptosis after a twenty-four hour treatment of Mn-doped ZnSe/ZnS peptide coated
QDs on macrophage cells in cell media. Results are in expressed in mean + s.d.,
n=6. ∆ p=0.02 (<0.05) and ∆∆ p=0.000002 (<<<0.01). UTC – untreated cells, N.S.
– not significant, RLU – relative luminescence units.

48 hour Viability: Figure 6.10 displays a 72% drop in viability with digitonin
(p=0.002 < 0.01) over the untreated, with similar decreases seen in the other positive
controls (staurosporine showing 52% less viability (p=0.002 < 0.01) and ionomycin
showing 49% less viability (p=0.0009 << 0.01). Continuing the trend started at twelve
hours, the cell viability with 0.25 µM QDs is on par with the positive controls, with a
decrease in viability by 62% (p=0.0002 << 0.01). Consistent with both 12 hour and 24
hour incubation periods, an inverse between viability and QD concentration is observed.
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0.03 µM concentration shows a statistically insignificant decrease of 3%, increasing to a
41% drop at 0.13 µM (p=0.002 < 0.01).
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Figure 6.10: Macrophage cell viability bar graph depicting the cytotoxic effect after
a forty-eight hours treatment of Mn-doped ZnSe/ZnS peptide coated QDs on
macrophage cells in cell media. Results are in expressed in mean + s.d., n=6. *
p=0.049 (<0.05), ** p=0.002 (<0.01), *** p=0.0002 (<<0.01). UTC – untreated
cells, N.S. – not significant, RFU – relative fluorescence units.

None of the QD concentrations showed any statistically significant cytotoxic
effects after 48 hours of incubations (Figure 6.11), though the positive controls show
significant increases in fluorometric intensity, with digitonin rising by 248% (p=0.047 <
0.05). On the other hand, staurosporine increased cytotoxicity by 419% (p=0.0004 <<
0.01) and ionomycin elevated the effects by 473% (p=0.0003 << 0.01).
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Figure 6.11: Macrophage cell cytotoxicity bar graph depicting the cytotoxic effect of
Mn-doped ZnSe/ZnS peptide coated QD from a forty-eight hour treatment on
macrophage cells. Results are in expressed in mean + s.d., n=6. UTC – untreated
cells, N.S. – not significant, RFU – relative fluorescence units.
At 4
8 hours, luminescence readings (Figure 6.12) displayed apoptosis elevated by
304% by staurosporine (p=0.00002 <<< 0.01), with the other two positive controls
significantly lower. Digitonin increased apoptosis by 81% (p=0.0006 << 0.01), and
ionomycin did the same by just 17% (p=0.04 < 0.05). The lowest QD concentration was
the only one statistically insignificant. Apoptosis was increased by 17% for 0.06 µM,
45% for 0.13 µM, and 60% for 0.25 µM (p=0.045 < 0.05, p=0.004 < 0.01 and p= 0.002 <
0.01, respectively).
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Figure 6.12: Macrophage cell induced apoptosis bar graph depicting induced
apoptosis after a forty-eight six-hour treatment of Mn-doped ZnSe/ZnS peptide
coated QDs on macrophage cells in cell media. Results are in expressed in mean +
s.d., n=6. ∆ p=0.045 (<0.05), ∆∆ p=0.004 (<0.01), and ∆∆∆ p=0.002 (<0.01). UTC –
untreated cells, N.S. – not significant, RLU – relative luminescence units.

6.5 Summary
The data obtained from the ApoTox-Glo® Triplex assay yielded a complete
profile for the effects of cell viability, cytotoxicity, and apoptosis from the peptide coated
ZnSe:Mn/ZnS QDs at four different concentrations for four different incubation times.
Noteworthy is the higher sensitivity to cell viability that becomes apparent at 12 hours
(Figure 6.4) and remains fairly consistent for 24 (Figure 6.7) and 48 hours (Figure
6.10). Most interesting is the fact that despite the drops in viability, the QDs show very
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little cytotoxic effect, particularly for 6, 12, and 48 hour incubation times, with an
exception for a statistically significant 315% increase in cytotoxicity for the most
concentrated 0.25 µM QD solution for 24 hours (Figure 6.8).
The main conclusion from the tests is that, despite their low cytotoxicity, these
particular QDs still seem to be having an unhealthy effect on the cells at higher
concentrations. Lowered viability without any increase in the cytotoxicity biomarker is
indicative of an antiproliferation effect on the cells. In the case of primary necrosis,
where all the cells die early, cytotoxicity may not be measurable in later testing times52. If
the cells where to significantly die earlier than the testing time then enzyme markers for
cytotoxicity can degrade early on, and cytotoxicity ends up being underestimated53.
However, in the case of the macrophage cells being treated with the QDs, there is a
measurable caspase activation from induced apoptosis at all four incubation times, as
seen from the luminescence measurements in figures 3, 6, 9, and 12, with a statistically
significant measurable increase in luminescence for the most concentrated 0.25 µM QD
for all 4 incubation times, so primary necrosis can be ruled out.
Overall, it would seem that there is very little cytotoxic effect on the macrophage
cells from the presence of the peptide coated ZnSe/ZnS:Mn QDs. However, it was
fortunate that the ApoTox-Glo® Triplex assay allows for more thorough testing on other
effects from the cells. The results outside of the cytotoxicity measurements show that
these QDs show a good deal of decreased viability and induced apoptosis, a result which
would have gone unnoticed had only cytotoxicity been tested.
We determined the safe concentration limits for these QD to be below 0.125 µM,
and the adverse effects associated with the viability decrease, cytotoxicity and apoptosis
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to scale with dosage/exposure concentration. We consider our QD to be good candidates
for in vivo experiments, but further studies exploring the mechanisms of the increased
caspase .activation and cytotoxicity at higher QD concentrations are needed
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Chapter 7
Conclusions and future work
Photoluminescent colloidal ZnSe:Mn/ZnS QDs have been synthesized and
optically and structurally characterized with repeatable results. The colloidal QDs exhibit
two different luminescence peaks at 597 nm and 487 nm wavelengths, by using 400 nm
and 436 nm excitation wavelengths, respectively. The 597 nm emission signal is
attributed to interatomic energy transitions in the Mn-dopant, and the 487 nm emission is
attributed to surface defects. As synthesized, and at high concentrations in chloroform,
the 597 nm emission has a high intensity with an 86.5% QE.
Conjugating cys-containing peptides to the QDs, which range between 4 and 14
AA residues, results in the lowering of QE. In addition, the excitation for the Mntransition blue shifts significantly to ~315 nm and the emission slightly blue shifts by a
few nm to ~595 nm. The surface defect emission disappears entirely after conjugating
peptides to the QDs. The drop in QE is attributed to a quenching effect that the peptides
have on the QDs. The amount of quenching varied with respect to the peptide
composition in the case of three different peptides: the remnant 4 AA residue Peptide
{Leu}{Arg}{Ser}{Cys}, the substrate 9 AA residue peptide
{Val}{Val}{Pro}{Leu}{Ser}{Leu}{Arg}{Ser}{Cys}, and a substrate 14 AA peptide
{Glu}{Asp}{Glu}{Asp}{Glu}{Val}{Val}{Pro}{Leu}{Ser}{Leu}{Arg}{Ser}{Cys}. The 4
AA and 9 AA peptides are basic with a charge of +1, and the 14 AA peptide is acidic
with a -4 charge. The QY of the peptide/QD conjugates with 4 AA have higher QY than
the 9 AA, and the 14 AA has a higher QY than the 4 AA peptide (9 AA < 4 AA < 14
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AA). The Zeta potentials for all three types of QD/peptide conjugates have negative
values, which does not support the idea that the QD/peptide conjugates with 9 AA and 4
AA peptides have a different surface charge than the conjugates with the 14 AA peptides.
In addition, the peptide/QD conjugates showed minimal sensitivity to active mouse
MMP-9s, particular at lower peptide densities. The peptide concentration during
bioconjugation was reduced to 0.1%, 1%, 10%, 33%, and 66% of the standard peptide
concentrations, essentially lowering the peptide to QD ratio during bioconjugation. 0.1%
and 66% dilutions showed minimal sensitivity to active MMP-9.
Furthermore, the ZnSe:Mn/ZnS QDs were successfully tethered to the surface of
glass slides, by partially coating them with MPTMS coupling agent and orbital shaking
the colloidal solution over OH-modified silica. The QDs maintain their fluorescence and
have an 8% QE when characterized on silica. The successful linking of the Cd-free
luminescent QDs to the surface of silica is a step towards the development of an in vivo
optical fiber biosensing system with QDs covalently bonded to the silica tip of the fiber.
Thorough cytotoxicity studies revealed the Cd-free colloidal peptide coated
ZnSe:Mn/ZnS QDs to still display cytotoxic properties when incubated with macrophage
cells at different time points and different QD concentrations. The concentrations which
showed no cytotoxic effects with regards to cytotoxicity, viability, and induced-apoptosis
were below 0.125 µM.
For future work, the sensitivity of the MMP-9 biosensors, developed and
experimented with in this dissertation, should be increased. Suggestions to increase
sensitivity would be to increase the QD to peptide ratio during bioconjugation, conjugate

121

energy acceptors/donors to the external ends of the peptides at the surface of QDs, run the
experiments at possibly higher peptide/QD conjugate concentrations, run the biosensing
experiments in buffer solutions designed for optimization of MMP-9 activity, as opposed
to CSF and water, and colloidal stability of the QDs biosensors in solution should be
enhanced, as the current biosensors would fall out of solution overnight for CSF and
buffer.
As the chemistry for linking these particular QDs to silica has been developed, it
still remains to link the QDs to silica and subsequently conjugate peptides to the linked
QDs, another step towards the completion of the in vivo biosensor.
In order to verify that the MMP-9s are indeed cleaving the peptides attached to
the QDs, gel electrophoresis experiments should be implemented. If the peptides are
being cleaved, the peptide/QD conjugates should decrease in overall size, which would
be discernable with gel electrophoresis.
In addition, cytotoxicity experiments should be repeated for different MMP
substrates conjugated to ZnSe:Mn/ZnS QDs, as we’ve only looked at one peptide
substrate. As was discussed in chapter 6, cytotoxicity of nanomaterials can be influenced
by surface molecules, surface charge, stability, and particle size. Different peptide
substrates have unique amino acid residue sequences and would therefore have their own
unique peptide properties such as hydrophobicity, charge, acidity, etc.
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